

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。



# CONTENTS



|    |  |    |   |
|----|--|----|---|
| 2  | CORPORATE INFORMATION  | 52 | CONSOLIDATED STATEMENT OF FINANCIAL POSITION    |
| 5  | RESULTS HIGHLIGHTS   | 54 | CONSOLIDATED STATEMENT OF CHANGES IN EQUITY     |
| 6  | MANAGEMENT DISCUSSION AND ANALYSIS   | 56 | CONDENSED CONSOLIDATED CASH FLOW STATEMENT      |
| 26 | CORPORATE GOVERNANCE AND OTHER INFORMATION                                 | 57 | NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT |
| 48 | REVIEW REPORT OF THE AUDITORS  | 93 | DEFINITION                                      |
| 50 | CONSOLIDATED STATEMENT OF PROFIT OR LOSS                                   |    |   |
| 51 | CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND<br>OTHER COMPREHENSIVE INCOME |    |   |





# CORPORATE INFORMATION



## BOARD OF DIRECTORS

### Executive Directors

Mr. HUANG Jian (*Chairman*)

Mr. ZHENG Wenbin

Mr. LI Youquan

Ms. HUANG Danyan

### Non-executive Directors

Mr. LIU Zhen

Mr. WANG Yalong

### Independent Non-executive Directors

Mr. XIAO Wei

Mr. CHEN Aihua

Mr. LAM Yiu Por

### Supervisors

Mr. ZHENG Feng

Ms. WEI Wei

Ms. ZHANG Ning

## AUDIT COMMITTEE

Mr. CHEN Aihua (*Chairman*)

Mr. XIAO Wei

Mr. LAM Yiu Por

## REMUNERATION AND APPRAISAL COMMITTEE

Mr. XIAO Wei (*Chairman*)

Mr. LI Youquan

Mr. CHEN Aihua

## NOMINATION COMMITTEE

Mr. XIAO Wei (*Chairman*)

Mr. CHEN Aihua

Ms. HUANG Danyan

6 +

B 6 +

6 B 6 +

6 m 6 B 6 +

9 +

2 % p 6

Z G ~ ý 6 % p 6

d 6 % p 6



## STRATEGY COMMITTEE

Mr. HUANG Jian (*Chairman*)

Mr. ZHENG Wenbin

Mr. LAM Yiu Por

· + % p 6

— —

## JOINT COMPANY SECRETARIES

Ms. XIONG Ting

Ms. LEUNG Kwan Wai

L © ® ! d ã

## H SHARE REGISTRAR

Tricor Investor Services Limited

17/F, Far East Finance Centre

16 Harcourt Road, Hong Kong

H p Ç N î ¾ ^

16

17

## AUTHORIZED REPRESENTATIVES

Mr. HUANG Jian

Ms. XIONG Ting

→ Æ p Œ

## AUDITOR

KPMG

*Certified Public Accountants*

Public Interest Entity Auditor registered in accordance with

the Accounting and Financial Reporting Council Ordinance

8th Floor, Prince s Building

10 Chater Road

Central, Hong Kong

è p <sup>a</sup>

<sup>a</sup>

«

10

8

## REGISTERED OFFICE IN THE PRC

Unit 1, Unit 301

No. 3, Xiangming Road

Xiamen Torch High-tech Zone (Xiang an)

Industrial Zone

Xiamen City, Fujian Province, the PRC

• 7 W | + ^

— —

3

301



## CORPORATE INFORMATION



### HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

22/F, Caizhui No. 188, Qianpu Road  
Siming District  
Xiamen City, Fujian Province, the PRC

< Å ĵ • 7 ô 8 ® Ã

188 22

### PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 1928, 19/F  
Lee Garden One, 33 Hysan Avenue  
Causeway Bay, Hong Kong

0 ¥ ô 8 ® Ã

33  
19 1928

### PRINCIPAL BANK

Xiamen Bank Co., Ltd. (Lianqian Branch)

ô » 8 Õ

— -

### HONG KONG LEGAL ADVISER

Han Kun Law Offices LLP  
Rooms 4301-10, 43/F, Gloucester Tower  
The Landmark, 15 Queen's Road Central  
Hong Kong

0 ¥ , ¥ \*

15  
43 4301-10

### COMPANY'S WEBSITE

<http://www.yanzhiwu.com>

® ! c g

<http://www.yanzhiwu.com>

### LISTING DATE

December 12, 2023

j 9 Ú ,

### STOCK SHORT NAME

YAN PALACE

p ... H

### STOCK CODE

1497

p ... p î

1497



## RESULTS HIGHLIGHTS

8

### RESULTS HIGHLIGHTS

Our revenue decreased by 4.22% from RMB1,059.30 million for the six months ended June 30, 2024 to RMB1,014.58 million for the six months ended June 30, 2025.

|  |          |       |
|--|----------|-------|
|  | 1,059.30 | 4.22% |
|  | 1,014.58 | w     |

Our gross profit increased by 2.67% from RMB513.80 million for the six months ended June 30, 2024 to RMB527.53 million for the six months ended June 30, 2025.

|  |        |       |
|--|--------|-------|
|  | 513.80 | 2.67% |
|  | 527.53 | w     |

Our net profit increased by 28.98% from RMB60.05 million for the six months ended June 30, 2024 to RMB77.45 million for the six months ended June 30, 2025.

|        |       |   |
|--------|-------|---|
|        | 60.05 |   |
| 28.98% | 77.45 | w |

Our adjusted net profit (non-IFRS measure)<sup>(1)</sup> increased by 35.54% from RMB60.05 million for the six months ended June 30, 2024 to RMB81.39 million for the six months ended June 30, 2025.

|                  |       |        |
|------------------|-------|--------|
|                  | —     |        |
| - <sup>(1)</sup> | 60.05 | 35.54% |
|                  | 81.39 | w      |

*Note:*

(1) The Company's adjusted net profit (non-IFRS measure) represents the net profit for the period, adjusted to add back equity-settled share-based payment expenses, which are non-cash in nature.

|     |   |   |
|-----|---|---|
| {   |   |   |
| (1) | — |   |
|     | — | w |



# MANAGEMENT DISCUSSION AND ANALYSIS

## MANAGEMENT DISCUSSION AND ANALYSIS

### BUSINESS REVIEW

In the first half of 2025, China's macro-economic policies continued to deliver sound results, and the economy maintained a stable and positive trend, demonstrating strong resilience. However, uncertain factors in the external environment persisted. Against this backdrop, the health industry became a key driver of economic growth, with multiple favorable factors, including policies, technology and capital, accelerating the industry's transformation and upgrade.

Leveraging its strong research and development capabilities, the Company continued to enrich its EBN product portfolio, successfully reaching a wider consumer base through a diversified and differentiated product strategy. At the same time, the Company upheld a prudent operational strategy to proactively respond to market changes and continued to consolidate and strengthen existing channels while focusing on the deployment of its KA channel. It actively explored the potential of lower-tier markets and accelerated the expansion for overseas business. By continuously optimizing production efficiency and effectively reducing production costs, the Company laid a solid foundation for enhancing product competitiveness. With certifications such as No. 1 in Premium EBN Sales, No. 1 in Traceable Bird's Nest Imports, and No. 1 in the China Brand Power Index, the Company has further strengthened its leading position in the industry.

#### 1. Product Innovation and Exploration to Expand Consumer Groups

In response to the diverse and differentiated needs of consumers, the Company firmly implemented the pure EBN, EBN+ and +EBN strategies, built a systematic framework of product development, covering R&D, iteration and innovation, and continuously improved the product structure to cover a wider range of segmented demand scenarios, with an aim to providing consumers with more comprehensive nourishment solutions.

During the Reporting Period, the Company actively expanded its consumer base for EBN products. In response to consumers' natural desire for hot EBN, the Company leveraged its patented supercritical process to launch Yan Palace Supercritical Hot EBN, offering a highly effective, warm and fresh ready-to-eat experience, integrating technological innovation into daily nourishment. To address people's emerging needs such as sleep and intestinal health, the Company started developing functional products of EBN + probiotics to further expand its EBN consumer base.

### 8 « ¥

|      |   |   |    |   |
|------|---|---|----|---|
| 2025 | u |   |    | u |
|      |   |   | u  | w |
|      | u |   |    | w |
|      | u |   |    |   |
|      | u | v |    |   |
|      |   |   | w  |   |
|      |   |   |    | u |
|      | u |   |    |   |
|      | u |   | KA | u |
|      |   | u |    | w |
|      |   |   | u  | u |
|      |   |   | w  | 2 |
|      |   | 3 |    | 3 |
| w    |   | u |    |   |
|      |   |   | v  | u |
|      | 2 |   | 3  | 2 |
| u    |   | v |    | 3 |
|      |   | u |    | u |
|      |   |   | u  |   |
|      |   |   | w  |   |
|      | u |   |    |   |
| w    |   |   |    | u |
|      |   |   | u  | u |
|      |   |   | v  |   |
|      | u |   |    | w |
|      |   | v |    | u |
|      | 2 | + | 3  | u |
|      |   |   | w  |   |



The Company relied on EBN porridge and other +EBN products to effectively cover diverse scenarios for EBN consumption. *Xiao Yan Nong* ( ) EBN porridge has been successfully applied to highly frequent scenarios such as breakfast and meal replacement, achieving rapid sales growth. In the first half of 2025, its sales reached RMB43.82 million, representing a 6.28% increase over the same period of last year. Meanwhile, during the 618 Shopping Festival, *Xiao Yan Nong* ( ) EBN porridge maintained its top position in the ranking of sales of EBN porridge on both platforms of Tmall and JD. This fully demonstrated the product's core competitiveness and brand influence in its niche market, laying a solid foundation for the continuous growth of the sales of EBN porridge.

Based on the new trend of nutritious products with diversified functions and snack-like forms, the Company has leveraged its accumulated experience of scientific research over years to establish the brand YANPEP EBN peptide, introducing oral EBN peptide, EBN peptide collagen essence drink, EBN peptide natural strontium water and other products with EBN peptide as the core ingredient. These products are both palatable and convenient, which is conducive to cultivating daily consumption habits among consumers, driving the innovation of EBN peptide products and leading the development of the EBN industry.

## 2. Strategic Upgrade of Sales Channels to Optimize Consumer Experience

In the first half of 2025, the Company optimized and upgraded its offline channels, actively explored online distribution channels, developed KA, overseas and other emerging channels, and continuously improved its sales network. Certified by Beijing Zhongyan Century Consulting Co., Ltd., the Company received a market position confirmation certificate of No. 1 in National Sales of Premium EBN for Nine Consecutive Years. During the Reporting Period, the Company's operating revenue reached RMB1,014.58 million.

|        |      |   |       |   |
|--------|------|---|-------|---|
|        | 2    | + | 3     | u |
|        |      |   | w     |   |
| v      |      |   |       | u |
| u      | 2025 |   |       |   |
| 43.82  | u    |   | 6.28% | w |
| u      | 618  | u |       | v |
|        | w    |   |       |   |
|        |      | u |       |   |
|        | w    |   |       |   |
|        |      | v |       |   |
| u      |      |   |       |   |
| YANPEP | u    |   |       | v |
|        |      | v |       |   |
|        |      |   | u     |   |
| u      |      |   |       | u |
|        | w    |   |       |   |



M # 4 Å ~ ±

(1) Offline Channels

During the Reporting Period, our total revenue generated from the offline business was RMB381.92 million, accounting for 37.64% of the Company's total revenue. As of June 30, 2025, the sales network consisted of 111 self-operated stores and 601 distributor-operated stores, totaling 712 stores. In April 2025, certified by Frost & Sullivan, the Company received a market position statement confirming its position as No. 1 in Number of Yan Palace EBN Specialty Stores in China. During the Reporting Period, the Company implemented an optimization and upgrading strategy ' ' by establishing a mechanism for store evaluation, optimizing resource allocation and encouraging distributors to iterate existing stores or open new stores, the Company achieved the goal of closing small stores and opening large stores to enhance the customer experience.

In the first half of 2025, 11 Yan Palace 3.0 flagship stores, officially commenced operations, including the store in the Tianjin MixC, the store in Deji Plaza of Nanjing and the flagship store in Xi'an, marking a new phase for the Company's offline channels. Yan Palace 3.0 flagship stores have achieved remarkable results in expanding store space, clarifying product zoning and optimizing customer experience, which contributes to the renewal of store image and the lift of brand image.

In 2024, China's urbanization rate for resident population has reached 67%, which has become one of the key factors driving China's consumption growth. In the first half of 2025, the Company continued to deepen its presence in lower-tier markets. On the one hand, the Company embarked on deploying its presence in the top 100 counties and gradually established a core county-level grid system. On the other hand, based on the consumption characteristics of lower-tier markets, the Company leveraged large street-side flagship stores as core touchpoints. By offering value-added services such as membership salons and EBN tasting sessions, it further unlocked the growth potential of lower-tier markets, created scenarios for in-depth communication with customers, and accurately identified and efficiently addressed the needs of consumer groups in the lower-tier markets.

(1) 8

|        |     |      |     |        |
|--------|-----|------|-----|--------|
| 381.92 | u   |      |     |        |
| 37.64% | w   | 2025 | 6   | 30 u   |
| 111    |     |      | 601 |        |
| u      |     | 712  | w   | 2025 4 |
|        |     |      | u   | 2      |
|        |     |      |     | 3      |
|        | w   |      | u   |        |
|        | u   |      |     | u      |
|        |     |      | u   | 2      |
| 3u     |     |      | w   |        |
| 2025   |     | u    |     |        |
| v      |     |      | v   |        |
| 11     | 3.0 |      | u   |        |
|        |     |      | w   | 3.0    |
|        |     |      | v   |        |
|        |     |      |     | u      |
|        |     |      |     | w      |
| 2024   | u   |      |     |        |
| 67%    | u   |      |     |        |
|        | w   | 2025 |     | u      |
|        |     |      | z   | u      |
|        |     |      | u   |        |
|        | w   |      | u   |        |
|        | u   |      |     |        |
|        | u   |      |     | v      |
|        |     |      | u   |        |
|        |     |      | u   |        |
| u      |     |      |     | w      |





M # 4 Å ~ ±

#### (4) New Channel Deployment

In the first half of 2025, the Company steadily boosted its international presence, and successively opened overseas stores in New York, U.S.A., Singapore and other locations, marking a key step in showcasing the unique appeal of Chinese nourishing culture to the world. At the same time, the Company accelerated its expansion into the KA channel through products such as customized EBN porridge and instant EBN, successfully entering Ole, Rainbow, CR Vanguard, Sungiven and other supermarket systems.

With respect to the cultural tourism business, the Company promoted the revenue growth through collaborations with key customers, factory visits and educational tours. Along with the stable development of the cultural tourism business, our customers have gained a deeper understanding of EBN culture, production process and the nutritional value through the visits to transparent factories, EBN cultural museums and EBN research institutes, deepening brand recognition and trust, and enhancing the Company's influence.

### 3. Driving Industry Development with R&D and Innovation

The Company established the Yan Palace EBN Research Institute in 2008, which dedicated to the comprehensive research into EBN ingredients, nutrition, health, process and products. In June 2025, the Company, together with the Xiamen Customs Technology Center and Fujian Agriculture and Forestry University, established the Joint Laboratory for Quality Control and Health Efficacy Application of EBN and EBN Peptide of Xiamen. To date, the Company has set up joint laboratories with the Xiamen Customs Technology Center, Peking University Health Science Center, Jiangnan University, South China University of Technology, and the National Research and Innovation Agency of Indonesia. Furthermore, the Company has partnered with institutions and universities, including the Chinese Academy of Medical Sciences, China Pharmaceutical University, Hong Kong University of Science and Technology, the National Quarantine Agency of Indonesia, China National Institute of Standardization and China National Research Institute of Food Fermentation Industry, creating the 1+7+N Research Platform to connect top universities and research institutions and facilitating the transition from academic research to product development. In the six months ended June 30, 2025, the Company was granted 27 national patents and published five papers.

#### (4) - → 8 1 ...

|      |      |   |   |    |
|------|------|---|---|----|
| 2025 | u    |   |   |    |
|      | u    |   | v |    |
|      |      | u |   |    |
|      | w    | u |   |    |
| v    |      |   |   | KA |
| u    | Olev | v |   | v  |
|      | w    |   |   |    |
|      |      | u |   |    |
| v    |      |   |   |    |
| w    |      |   |   | u  |
|      |      | v |   |    |
|      | u    |   |   | v  |
|      |      |   | u |    |
| u    |      | w |   |    |

#### 3 e ø ¼ ï ô - " 8 ï •

|      |                |       |    |              |
|------|----------------|-------|----|--------------|
| 2008 |                |       |    | u            |
|      | v              | v     | v  | v            |
|      | w              | 2025  | 6  | u            |
|      | v              |       |    | 2            |
|      | <sup>3</sup> w | u     |    |              |
| v    |                |       | v  | v            |
| v    |                |       |    |              |
|      | u              |       |    | v            |
|      | v              |       | v  |              |
|      | v              |       |    | v            |
| u    | <sup>2</sup>   | 1+7+N |    | <sup>3</sup> |
|      | u              |       |    |              |
| w    | 2025           | 6     | 30 | 6            |
|      |                | 27    | u  | 5            |
|      |                |       |    | w            |



(1) EBN Technology Research and Development

In June 2025, with respect to the research of EBN raw materials, the Company, in collaboration with domestic scientific research institutions, has completed the research on the compositional analysis and content difference of the EBN proteome from different origins, which provides the scientific basis for selecting high-quality EBN raw materials.

The Company has also achieved a number of results in the understanding and scientific evidence-based research of EBN. In January 2025, the Company completed joint research on the structure and efficacy of sialic acid in EBN with Nanchang University and Jiangnan University respectively, systematically explaining the unique O-linked and N-linked structures of sialic acid in EBN, as well as the difference in efficacy in inhibiting pathogens and protecting intestinal health that far exceeds that of biosynthetic sialic acid (N-acetylneuraminic acid). In May 2025, the paper on the blood pressure lowering effect of EBN, being Identification, screening and transepithelial transport of ACE inhibitory peptides derived from gastrointestinal digested edible bird s nest , jointly studied with Jiangnan University, was published in the international SCI-indexed journal, being Food Bioscience (JCR Q1 zone, impact factor 5.9). The paper reveals that appropriately high-temperature stewing (115 , 121 ) can promote the production of functional active peptides in EBN, and further clarifies the fine composition and active molecular mechanism of active peptides in bird s nests that produce antihypertensive effects. In June 2025, in collaboration with Xiamen University, the Company utilized human subject research data to verify that bird s nests can effectively increase the sialic acid content in the blood and improve physical fitness and skin quality, providing high-level evidence for the wellness benefits of bird s nests.

The Company also transformed a number of research results during the Reporting Period and obtained market position certificates from Shangpu Group such as Pioneer of Finely Stewed EBN and Pioneer of Fresh and Hot EBN in May and June respectively.

(1) 0 J Å ! ¼ i

2025 6 u u

u w

w 2025 1 u

u Oë v Në u

v

— Në

- z 2025 5 u

<sup>2</sup> Identification, screening and transepithelial transport of ACE inhibitory peptides derived from gastrointestinal digested edible bird s nest—

ACE v  
- 3 SCI

<sup>a</sup> Food Bioscience—JCR Q1 u

5.9~ u —115 v

121 -

u

z 2025 6 u

u v

u

w

u u

5 6 2 3

2 3 w



M # 4 Å ~ ±

(2) EBN Peptide Technology Research and Development

Among the Company's seven established joint laboratories, three specialized laboratories focus on the in-depth research and application transformation of EBN peptide. As a significant achievement in EBN deep processing, EBN peptide represents a new direction for the modernization and functionalization of EBN. It is a modern interpretation of the millennium-old EBN health culture and embodies the mission of Yan Palace to shoulder industry responsibilities and lead the future of EBN. Yan Palace leveraged the in-depth research and application of EBN peptide, a core active ingredient, to continuously expand the boundaries of EBN's application.

With respect to the in-depth research on the structure-activity relationship of EBN peptide, the Company published a research result entitled Edible bird's nest peptide (EBNP) with high whitening activity: Sequences analysis, whitening activity characterization and molecular docking study in the international SCI-indexed journal, being Journal of Functional Foods (JCR Q2 zone, impact factor 4.0). The result of the study shows that EBN peptide can downregulate the expression of tyrosinase, MITF, TYR, TYRP1 and TYRP2 in relation to melanin synthesis at the cellular level, thereby significantly inhibiting the melanin synthesis and exerting a whitening effect. At the same time, the study clarifies the peptide sequence and fine structure of the EBN peptide that plays the abovementioned role, providing scientific evidence for the structure-activity relationship of the EBN peptide. In February 2025, the Company jointly published the research results of EBN peptide with South China University of Technology, being Bioactive peptides from edible Bird's nest: Pivotal players in skin mechanic injury repair in the international SCI-indexed journal, being Food Bioscience (JCR Q1 zone, impact factor 5.9), revealing that EBN peptide has the biological activity of promoting dermal collagen synthesis and skin repair, and the effect is stronger than biosynthetic sialic acid (N-acetylneuraminic acid).

(2) Edible bird's nest peptide

7 u 3  
w  
u v  
u  
u  
v  
w  
u  
w  
u  
2 Edible bird's nest peptide (EBNP) with high whitening activity: Sequences analysis, whitening activity characterization and molecular docking study— (EBNP){  
v  
- 3 SCI  
a Journal of Functional Foods←JCR Q2  
u 4.0 u  
v MITFv  
TYRv TYRP1v TYRP2 u  
u  
u  
w  
2025 2  
2 Bioactive peptides from edible Bird's nest: Pivotal players in skin mechanic injury repair—  
{  
- 3 SCI a Food  
Bioscience←JCR Q1 u  
5.9 u  
v u  
—Në  
w



With respect to the EBN peptide preparation technology, in light of the patent named "A type of bird's nest peptides preparation method and application with the efficacy of promoting cellular repair and high moisturization and whitening", the Company was certified by Shangpu Group in March 2025, and obtained the market position certificate of "the world's first independent invention patent authorization for EBN peptide with clear efficacy and application", which further consolidated its R&D and innovation strength.

Meanwhile, during the Reporting Period, Yan Palace launched its independent brand, YANPEP EBN Peptide, with the simultaneous release of three new EBN peptide products, namely oral EBN peptide, EBN peptide collagen essence drink, and EBN peptide natural strontium water, opening up new application scenarios for EBN. In June 2025, YANPEP oral EBN peptide completed a two-month human clinical efficacy evaluation, further demonstrating its excellent performance in boosting energy, improving sleep and enhancing skin quality, which injected new momentum into the research and development of the EBN peptide product series and the launch of new products.

In the future, the Company will continue to focus on researching and developing the core technology of EBN and EBN peptide. On the one hand, it will deepen basic research, cooperate with universities and research institutions to analyze the molecular mechanism of the active ingredients of EBN peptide, optimize the preparation process and bioavailability of EBN peptide and strengthen technological advantages. On the other hand, it will accelerate the innovation for application and expand the product forms of EBN peptide in multiple scenarios based on the wellness needs of different groups of people, so as to provide consumers with more scientific and efficient wellness solutions.

u  
2 v 3  
2025 3 u  
2 3 u  
w  
u  
2 YANPEP 3 u  
v  
u w u  
YANPEP 2025 6  
2 u  
v v  
u  
w  
u  
u  
u  
z u  
u  
v w




M # 4 Å ~ ±

#### 4. Integration of High-quality Resources to Boost Brand Development and Enhance Industry Leadership

On the China Brand Power Index<sup>SM</sup> (C-BPIfi) EBN brand ranking, the Company has been ranked the first in the industry for six consecutive years, leading the industry in terms of brand power.

During the Reporting Period, the Company leveraged its multi-faceted brand ambassador matrix, including Ms. Gong Li ( ) and Mr. Wang Yibo ( ), to reach diverse consumer groups. Furthermore, the Company gradually initiated IP collaborations to further expand its consumer base. Short video clips featuring relevant ambassadors, collaborating artists and leading influencers were released on platforms such as Douyin, JD and Tmall, which has effectively boosted the brand exposure.

The Company continued to collaborate with restaurants and hotels to launch EBN-featured Afternoon Tea Sets and EBN Banquets, creating the frequent scenarios for social consumption. As of June 30, 2025, it had established partnerships with seven restaurants, including LA CHANSONNIERE and Lu Shang Lu, as well as six hotels, including China World Summit Wing, Beijing and Shangri-La Shenyang. Leveraging its premium positioning and expertise, the Company offered customers refined EBN experience, elevating EBN from a traditional tonic into a modern consumer product combining wellness, nourishment and social attributes. In light of the high-quality and stable consumer base and brand endorsements of its partners, the Company further strengthened its brand image.







M # 4 Å ~ ±

The Company spearheaded the drafting of the Calculation Approach for Carbon Footprint of EBN Products. This approach will build a refined carbon footprint calculation model covering the entire life cycle of an EBN product, from raw material tracing, production and processing, packaging and transportation, consumption, and waste disposal. The approach will clarify the boundaries for data collection and calculation methods, filling gaps in the industry and leading the industry's green and low-carbon transformation. Furthermore, the Yan Palace EBN smart factory, which has been actively practicing green intelligent manufacturing, received green environmental certifications such as the Product Carbon Footprint Verification Statement and the Greenhouse Gas Verification Statement in January 2025.

### OUTLOOK

In 2025, the health industry has entered a stage of strategic development, driven by continuous policy empowerment, stabilizing market environment and growing health demand. However, with the lingering external challenges, the Company is in a phase of strategic transformation and upgrading and in the face of substantial challenges. Therefore, the Company will continue to deepen its core strategy of tapping deeper into the value of bird's nests and expanding the health ecosystem, focusing on the diverse and personalized needs of consumer groups and launching more comprehensive nourishment solutions, so as to strengthen its leadership in the blue ocean market of healthcare. The Company will advance the implementation of this core strategy through three key approaches, being brand enhancement, product innovation, and channel expansion.

The Company will continue to deepen its brand strategy and enhance its brand value and influence across multiple dimensions. Going forward, it will keep building a multi-faceted ambassador matrix, leveraging high-quality resources such as artists and influencers to precisely reach and deeply engage with high-net-worth customers. It will also meticulously curate a series of community events, including golf membership events, private EBN banquets and VIP concert rooms, to enhance brand value and build deep connections with customers through immersive experiences. Meanwhile, it will deepen strategic collaborations with high-quality business partners, such as those in the hotel and restaurant sectors, to integrate the brand's essence into the high-quality lifestyles of its target customers, aiming to become a creator and companion for their beauty and wellness.

a  
«W v v  
u u  
u u 2025 1  
2 3  
3 u  
W

### Ã {

2025 u v  
w u u  
u u w u  
2 u 3  
u u  
u u 2  
3 3 2 3 u  
W

u u  
w v u  
z  
v v VIP u  
u z v  
u  
W



The Company's expansion into innovative products and EBN-related business extensions is currently in the phase of market cultivation and is still undergoing exploration and incubation. The Company is committed to fully releasing the growth potential and market value of this product matrix in the future. It also continues to iterate and upgrade existing products and develop new products that precisely meet consumer needs to continuously enrich its product portfolio. In relation to the pure EBN products, the Company is iterating core products such as *One Nest* ( ) and Freshly Stewed Bird's Nest ( ) to optimize production efficiency, strengthen product competitiveness and strengthen its leading position in the industry. In relation to the EBN+ and +EBN products, the Company is accelerating the research and development of new products, launching new product series such as EBN porridge and EBN peptide and developing innovative products such as EBN vials to expand coverage of its targeted customer base.

To further improve its sales network, the Company will focus on optimizing stores in core cities, building a county-level sales network, expanding the KA channel and exploring overseas markets. Based on its strategy of opening large stores in core cities, the Company will continue to open 3.0 flagship stores in the second half of the year and advance the launch of Yan Palace's Shanghai Member Center, comprehensively enhancing the offline experience. Focusing on the top 100 counties, the Company will establish a sales network system in lower-tier markets through standardized and asset-light stores. The Company will strengthen its partnerships with KA and convenience-store channels, creating new pillars of growth by entering large supermarket chains. Furthermore, the Company will actively expand into overseas markets, adopting Singapore as a hub to reach more regions and enhance its international competitiveness.

The Company will uphold the corporate vision of leading the global bird's nest industry and building a century-old national brand ( , ). Relying on its excellent product strength, extensive channel layout and strong scientific research capabilities, the Company will further strengthen its leading position in the industry and actively promote the high-quality development of the health industry.



u w  
u  
u u  
w<sup>2</sup> u<sup>3</sup> u  
v u u  
u z<sup>2</sup> +<sup>3</sup>  
<sup>2</sup> + <sup>3</sup> u u v  
u w  
u  
v v KA  
w u  
3.0 u z  
u u  
z KA  
u u  
z u  
u w  
<sup>2</sup> u  
<sup>3</sup> u v  
u u  
u w



MANAGEMENT DISCUSSION AND ANALYSIS  
M # 4 Å ~ ±

FINANCIAL REVIEW

The following discussions are based on the financial information and notes set out in other sections of this interim report and should be read in conjunction with them.

Revenue

Our revenue was mainly derived from sales and distribution of EBN products.

Our revenue decreased by 4.22% from RMB1,059.30 million for the six months ended June 30, 2024 to RMB1,014.58 million for the six months ended June 30, 2025. The following table sets forth a breakdown of our revenues by product categories for the six months ended June 30, 2024 and 2025.

|                        |     | Six months ended June 30,<br>Ú - Ü g d Ú ß - H Ü<br>2025<br>Z g Z ž Ě |              |                  |              |
|------------------------|-----|---|--------------|------------------|--------------|
|                        |     | RMB000<br>[ O Æ w ©   |              | RMB 000          |              |
|                        |     |   | %            |                  | %            |
| Pure EBN products      |     | 896,817   | 88.4         | 926,319          | 87.4         |
| EBN+ and +EBN products | + + | 111,003   | 10.9         | 124,698          | 11.8         |
| Others <sup>(1)</sup>  | (1) | 6,761   | 0.7          | 8,287            | 0.8          |
| <b>Total</b>           | <   | <b>1,014,581</b>  | <b>100.0</b> | <b>1,059,304</b> | <b>100.0</b> |

Note:

(1) Include non-EBN products such as snacks and rice dumplings etc.

*Pure EBN products.* Revenue generated from pure EBN products mainly represents the revenue generated from sales of pure EBN products primarily consisting of *One Nest* ( ), Freshly Stewed Bird's Nest ( ), other bottle-canned bird's nest and dried EBN. Our revenue generated from the sales of pure EBN products decreased by 3.18% from RMB926.32 million for the six months ended June 30, 2024 to RMB896.82 million for the six months ended June 30, 2025, primarily due to decrease in sales of *One Nest*, Freshly Stewed Bird's Nest and dried EBN.



M # 4 Å ~ ±

*EBN+ and +EBN products.* Revenue generated from EBN+ and +EBN products mainly represents the revenue generated from sales of EBN+ and +EBN products. Our revenue generated from the sales of EBN+ and +EBN products decreased by 10.99% from RMB124.7 million for the six months ended June 30, 2024 to RMB111.0 million for the six months ended June 30, 2025.

+ + w + +  
w + +  
124.7 10.99%  
111.0 w

*Others.* Our revenue generated from the sales of other products decreased by 18.46% from RMB8.29 million for the six months ended June 30, 2024 to RMB6.76 million for the six months ended June 30, 2025.

w 8.29  
18.46%  
6.76 w

### Cost of sales

Our cost of sales primarily consisted of cost of raw materials, employee benefits expenses, production costs and courier fees.

### V / Ó I

Our cost of sales decreased by 10.72% from RMB545.51 million for the six months ended June 30, 2024 to RMB487.05 million for the six months ended June 30, 2025.

v w v  
545.51 10.72%  
487.05 w

### Gross profit and gross profit margin

Our gross profit increased by 2.67% from RMB513.80 million for the six months ended June 30, 2024 to RMB527.53 million for the six months ended June 30, 2025.

ã ; ÷ ã ;  
513.80 2.67%  
527.53  
w

Our gross profit margin for the six months ended June 30, 2025 was 51.99% as compared to 48.50% for the six months ended June 30, 2024. The increase in gross profit margin was attributable to the steady improvement of the production efficiency through the intelligent manufacturing upgrades and process improvements of the new factory, which has effectively promoted the optimization and upgrades of the cost structure.

u u  
51.99%u  
48.50%u  
u u w

### Selling and distribution expenses

Our selling and distribution expenses primarily consisted of (i) advertising and promotion fees and (ii) employee benefits expenses. Our selling and distribution expenses decreased by 8.70% from RMB365.27 million for the six months ended June 30, 2024 to RMB333.48 million for the six months ended June 30, 2025, which was primarily attributable to a reduction in the Group's advertising fees in light of the macro-economic situation, we proactively adjusted our sales strategy and effectively increased the input-output ratio, which resulted in a decrease in the selling expense ratio.

V / ÷ ¾ V š Ō  
(i)  
z (ii) w  
365.27 8.70%  
333.48 u  
{  
u u u  
w



MANAGEMENT DISCUSSION AND ANALYSIS  
M # 4 Å ~ ±

Administrative expenses

Our administrative expenses primarily consisted of (i) employee benefits expenses and (ii) consulting service fee which primarily consisted of expenses in connection with strategic and management consulting services. Our administrative expenses increased by 6.36% from RMB62.60 million for the six months ended June 30, 2024 to RMB66.58 million for the six months ended June 30, 2025, which was primarily attributable to an increase in the equity-settled share-based payment expenses.

| A š Ő |   | (i) | z     | (ii) |
|-------|---|-----|-------|------|
| —     |   |     |       |      |
| ~ w   |   |     | 62.60 |      |
| 6.36% |   |     |       |      |
| 66.58 | u |     |       | w    |

Research and development expenses

Our research and development expenses decreased by 8.17% from RMB12.36 million for the six months ended June 30, 2024 to RMB11.35 million for the six months ended June 30, 2025, as we optimized and streamlined our experimental design, reducing the expenses on materials for research and development.

| ¼ i š Ő |   |       |       |   |
|---------|---|-------|-------|---|
| 12.36   |   | 8.17% |       |   |
|         | u |       | 11.35 |   |
|         | u |       |       | w |

Other net income

Our other net income primarily consisted of (i) government grants and (ii) interest income. Our other net income decreased by 20.75% from RMB7.97 million for the six months ended June 30, 2024 to RMB6.32 million for the six months ended June 30, 2025, which was primarily attributable to a decrease in the interest income.

| l ü × ] |   | (i) | z    | (ii) |
|---------|---|-----|------|------|
| w       |   |     | 7.97 |      |
| 20.75%  |   |     |      |      |
| 6.32    | u |     |      | w    |

Finance cost

Our finance costs primarily consisted of interest expenses on our lease liabilities. Our finance costs decreased by 9.23% from RMB3.53 million for the six months ended June 30, 2024 to RMB3.21 million for the six months ended June 30, 2025, which was primarily attributable to a decrease in the interest expenses on our lease liabilities.

| ì \  |   |  |      |       |
|------|---|--|------|-------|
| w    |   |  | 3.53 | 9.23% |
| 3.21 | u |  |      |       |
|      | w |  |      |       |

Income tax

Our income tax increased by 81.51% from RMB17.96 million for the six months ended June 30, 2024 to RMB32.60 million for the six months ended June 30, 2025, which was primarily attributable to an increase in the profits.

| Ô { ü |   |        |       |   |
|-------|---|--------|-------|---|
| 17.96 |   | 81.51% |       |   |
|       | u |        | 32.60 |   |
|       |   |        |       | w |



M # 4 À ~ ±

### Profit for the period

As a result of the foregoing, our profit for the period increased by 28.98% from a net profit of RMB60.05 million for the six months ended June 30, 2024 to a net profit of RMB77.45 million for the six months ended June 30, 2025.

|                       |        |       |
|-----------------------|--------|-------|
| Profit for the period | 60.05  |       |
| Change                | 28.98% | 77.45 |

### Adjusted net profit for the period (non-IFRS measure)

In order to supplement our consolidated financial statements presented in accordance with the IFRSs, we use adjusted net profit (non-IFRS measure) as an additional financial measure, which is not required by, or not presented in accordance with the IFRSs. Our adjusted net profit (non-IFRS measure) represents the net profit, adjusted to add back equity-settled share-based payment expenses for the corresponding period. Equity-settled share-based payment expenses are adjusted for as they are non-cash in nature. We believe that the non-IFRS measure facilitates the analysis and comparison of our operating performance.

|   |        |       |
|---|--------|-------|
| Adjusted net profit for the period (non-IFRS measure) | 60.05  | 77.45 |
| Change  | 28.98% | 77.45 |

For the six months ended June 30,  
 2025 2024  
 RMB000 RMB 000  
 [ O A E w ©

|  |                                    | 2025   | 2024   |
|--|------------------------------------|--------|--------|
| Profit and total comprehensive income for the period | , « ; — ħ < CE & x B               | 77,451 | 60,045 |
| Add:   | {                                  |        |        |
| Equity-settled share-based payment expenses          |                                    | 3,942  |        |
| Adjusted net profit (non-IFRS measure)               | ¾ A E ; —<br>€ ç 7 ç ì S _ A E Ž ) | 81,393 | 60,045 |



MANAGEMENT DISCUSSION AND ANALYSIS  
 管理層討論及分析

Liquidity, financial resources and capital structure

The primary uses of cash are to fund the daily operations of the business of the Group. For the six months ended June 30, 2024 and 2025, we financed our capital expenditures and working capital requirements primarily through cash generated from our operating activities. Going forward, we believe that our liquidity requirements will be satisfied with a combination of cash flows generated from our operating activities, the gross proceeds from the Global Offering, bank loans and other borrowings, and other funds raised from the capital markets from time to time. As of June 30, 2025, the Group had not used any financial instruments for hedging purposes.

We have continued to maintain a healthy and sound financial position and have followed a set of funding and treasury policies to manage our capital resources and mitigate potential risks involved. Our current assets decreased from approximately RMB1,013.52 million as of December 31, 2024 to approximately RMB890.95 million as of June 30, 2025, primarily due to a decrease in the inventories as a result of the fluctuation in sales during the peak season and the off season.

Cash flows

As of June 30, 2025, our cash and cash equivalents primarily consisted of cash at banks and were denominated in RMB and HKD. Our total cash and cash equivalents increased by 23.25% from RMB420.51 million as of December 31, 2024 to RMB518.29 million as of June 30, 2025, primarily attributable to an increase in the retained profits.

Foreign exchange risk management

Our functional currency is RMB. Our business is principally conducted in RMB, and substantially all of our assets are denominated in RMB. Foreign exchange risk arises when commercial transactions or recognized assets and liabilities are denominated in a currency that is not our functional currency. We are subject to foreign exchange risk arising from commercial transactions and recognized assets and liabilities which are denominated in non-RMB.

流動性、財務資源及資本結構

|        |   |   |          |
|--------|---|---|----------|
| w      |   |   |          |
|        | u | w | u        |
| u      |   |   |          |
| v      |   | v |          |
| u      |   |   |          |
| w      |   |   | u        |
|        |   |   | w        |
|        |   |   | u        |
|        |   | w |          |
|        |   |   | 1,013.52 |
| 890.95 | u |   |          |
|        | w |   |          |

現金流量

|        |   |   |        |
|--------|---|---|--------|
|        |   | u |        |
|        |   | u |        |
| w      |   |   | 420.51 |
| 23.25% |   |   |        |
| 518.29 | u |   | w      |

外幣匯兌風險管理

|   |   |   |   |
|---|---|---|---|
|   |   | w |   |
|   | u |   |   |
| w |   |   | w |
|   |   |   | w |



M # 4 Å ~ ±

We recognized net foreign exchange gains of RMB0.01 million for the six months ended June 30, 2025.

0.01 w u

We have not implemented any hedging arrangements. We manage our foreign exchange risk by closely monitoring the movement of the foreign currency rates. We will mitigate such a risk by constantly reviewing the economic situation and foreign exchange risk, and applying hedging measures when necessary.

w u w u w

### Capital expenditure

I š Ō

For the six months ended June 30, 2025, our total capital expenditure was approximately RMB18.83 million, compared to approximately RMB97.62 million for the six months ended June 30, 2024. Our capital expenditure primarily consisted of payments for purchase of equipment and intangible assets. We funded these expenditures with cash generated from our operations and financing activities.

18.83 u u 97.62 w w w w

### Capital commitments

I Ō Ä

As of December 31, 2024 and June 30, 2025, we had capital commitments of RMB8.30 million and RMB6.93 million, respectively, primarily in connection with (1) the remaining amount of payments expected to be made in the future for the purchase of long-term assets; and (2) the amount of payments for short-term leases within the next period.

u 8.30 6.93 u (1) z (2) w

### Contingent liabilities

Đ í À

As of June 30, 2025, we did not have any material contingent liability, guarantee or any litigation or claim of material importance, pending or threatened against any member of the Group.

u v w

### Future plans for material investments and capital assets

}³ ¿ I \* Y J 8 Œ

Save as disclosed in the section headed Future Plans and Use of Proceeds in the Prospectus and in this interim report, as of June 30, 2025, we did not have detailed future plans for material investments and capital assets.

2 3 u w

### Material acquisitions and disposals of subsidiaries and affiliated companies

} × ... ¿ / • © ! ¿ L n © !

Save as disclosed in this interim report, for the six months ended June 30, 2025, we did not have any material acquisitions or disposals of subsidiaries and affiliated companies.

u u w



MANAGEMENT DISCUSSION AND ANALYSIS  
M # 4 Å ~ ±

Pledge of assets

As of June 30, 2025, we did not pledge any of our assets.

\* / å

w

u

Net current assets

As of December 31, 2024 and June 30, 2025, our net current assets amounted to RMB402.04 million and RMB375.88 million, respectively. The decrease in our net current assets was primarily attributable to a decrease in the inventories as a result of the fluctuation in sales during the peak season and the off season.

t \*

u

402.04

375.88

w

w

Borrowings and Indebtedness

Our indebtedness consisted primarily of lease liabilities. The following table sets forth a breakdown of our indebtedness as of the dates indicated.

> › ç Å

w

w

|                          |         | As of<br>June 30,<br>2025                      | As of<br>December 31,<br>2024 |
|--------------------------|---------|--|-------------------------------|
|                          |         | Ú Z g Z ž Ě<br>- Ü g d Ú<br>(RMB in thousands) | -                             |
| Current indebtedness     | C , Å   |  |                               |
| Lease liabilities        |         | 29,830   | 25,267                        |
| Non-current indebtedness | ç C , Å |  |                               |
| Lease liabilities        |         | 96,391   | 105,048                       |
| Total                    | <       | 126,221  | 130,315                       |

As of June 30, 2025, we had no outstanding balance of borrowings. In addition, we had banking facilities of RMB197.0 million, none of which was utilized.

u

w

u

197.0

u

w



MI

M # 4 À ~ ±

o i a



# CORPORATE GOVERNANCE AND OTHER INFORMATION



## INTERESTS AND SHORT POSITIONS OF THE DIRECTORS, SUPERVISORS AND THE CHIEF EXECUTIVE OF OUR COMPANY IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF OUR COMPANY AND ITS ASSOCIATED CORPORATIONS

As of June 30, 2025, to the best knowledge of the Directors, the interests and short positions of the Directors, Supervisors and chief executive of the Company in the Shares, underlying Shares or debentures of the Company or any of our associated corporations (within the meaning of Part XV of the SFO), which were required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO); or (b) pursuant to Section 352 of the SFO, to be entered in the register referred to therein; or (c) to be notified to the Company and the Stock Exchange pursuant to the Model Code, were as follows:

Table with 4 columns: Name, Capacity/Nature of interest, Number of H Shares, and Approximate percentage in our total share capital & p l < X.

| Name                     | Capacity/Nature of interest                              | Number of H Shares <sup>(1)</sup> | Approximate percentage in our total share capital & p l < X |
|--------------------------|--|-----------------------------------|---|
| 姓名                       | ... J Æ B Ì /  | H p p ... p Ž <sup>(1)</sup>      | Y ? Ò õ ± â   |
| Mr. Huang <sup>(4)</sup> | Beneficial owner   | 4,335,000 (L)                     | 0.93%   |
|                          | Interest held jointly with another person <sup>(2)</sup> | 75,147,185 (L)                    | 16.14%  |
|                          | Interest in controlled corporation <sup>(3)</sup>        | 91,785,560 (L)                    | 19.72%  |
|                          |  | 29,000,000 (S)                    | 6.23%   |
|                          | Interest in controlled corporation <sup>(4)</sup>        | 8,208,320 (L)                     | 1.76%   |



CORPORATE GOVERNANCE AND OTHER INFORMATION  
 7 # ç l ü ! 1

| Name        | Capacity/Nature of interest                              | Number of H Shares <sup>(1)</sup> | Approximate percentage in our total share capital & p l < X |
|-------------|--|-----------------------------------|---|
| ‘ ¼         | ... J Æ B Ì /  | H p p ... p Ž <sup>(1)</sup>      | Y ? Ö õ ± â   |
| Mr. Zheng   | Beneficial owner   | 33,273,040 (L)                    | 7.15%   |
|             | Interest held jointly with another person <sup>(2)</sup> | 137,578,025 (L)                   | 29.55%  |
|             |  | 29,000,000 (S)                    | 6.23%   |
|             | Interest of spouse <sup>(5)</sup>                        | 8,625,000 (L)                     | 1.85%   |
| Mr. Li      | Beneficial owner   | 33,249,145 (L)                    | 7.14%   |
|             | Interest held jointly with another person <sup>(2)</sup> | 146,226,920 (L)                   | 31.41%  |
|             |  | 29,000,000 (S)                    | 6.23%   |
| LIU Zhen    | Beneficial owner   | 12,059,675 (L)                    | 2.59%   |
|             | Interest in controlled corporation <sup>(6)</sup>        | 60,000,000 (L)                    | 12.89%  |
| WANG Yalong | Interest in controlled corporation <sup>(7)</sup>        | 38,857,460 (L)                    | 8.35%   |



- (1) The letter L denotes the person's long position in the Shares and the letter S denotes the person's short position in the Shares.
- (2) (i) Mr. Huang, our founder, chairman and executive Director; (ii) Xiamen Suntama, an entity controlled by Mr. Huang; (iii) Mr. Zheng, our vice chairman and executive Director; and (iv) Mr. Li, our general manager and executive Director, are acting in concert (Mr. Huang, Mr. Zheng, Mr. Li and Xiamen Suntama, together the Concert Parties). See History, Development and Corporate Structure - Concert Party Arrangement in the Prospectus for more information. The equity interest held by Jinyan Tengfei LP (the employee incentive share platform controlled by Mr. Huang, who is the general partner of such limited partnership) and by Ms. Xue (the spouse of Mr. Zheng), are also deemed to be controlled by the Concert Parties pursuant to the Listing Rules.
- (3) Xiamen Suntama is controlled by Mr. Huang as of June 30, 2025. Mr. Huang is therefore deemed to be interested in the Shares held by Xiamen Suntama under the SFO.
- (4) As of the June 30, 2025, Mr. Huang was the sole general partner of Jinyan Tengfei LP. Mr. Huang is deemed to be interested in the Shares in which Jinyan Tengfei LP is interested in.
- (5) Ms. Xue is the spouse of Mr. Zheng. Accordingly, Mr. Zheng is deemed to be interested in the same number of Shares of Ms. Xue is interested in for the purpose of the SFO.
- (6) Xiamen Guangyao Tianxiang Investment Co., Ltd. is the sole general partner of Guangyao Tianxiang LP and is therefore deemed to be interested in the Shares held by Guangyao Tianxiang LP under the SFO. LIU Zhen held approximately 80% of the limited partnership interests of Guangyao Tianxiang LP and controls Xiamen Guangyao Tianxiang Investment Co., Ltd. as of the date of this interim report. LIU Zhen is therefore deemed to be interested in the Shares held by Guangyao Tianxiang LP under the SFO.
- (7) WANG Yalong held approximately 45% of Beijing Yanshi Investment Management Center (Limited Partnership) ( ) as of June 30, 2025, which is the general partner of Hongyan Investment LP. WANG Yalong is therefore deemed to be interested in the Shares held by Hongyan Investment LP under the SFO.

Save as disclosed above, as of June 30, 2025, none of the Directors, Supervisors or chief executive of the Company had or was deemed to have any interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which would be required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO); or which would be required to be recorded in the register to be kept by the Company pursuant to Section 352 of the SFO, or which would be required, pursuant to the Model Code, to be notified to the Company and the Stock Exchange.

(1) L<sup>3</sup> u<sup>2</sup> S<sup>3</sup>  
w

(2) (i) u v z  
(ii) u z (iii) z (iv) v  
v u<sup>2</sup> v  
3 w e 3 w  
— — — —  
w

(3) w u u u w

(4) u w w w

(5) u w u w

(6) u u u u  
w 80% w u  
u w

(7) — 45% w u  
u w

u v —  
XV v XV 7  
8 — z  
352 u w



### SUBSTANTIAL SHAREHOLDERS INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

ô p õp... ¿ ' ëp... •Y Æ  
B ¿ ñ Q

As of June 30, 2025, to the best knowledge of the Directors, the following persons, other than Directors, Supervisors or chief executive of the Company, had interests or short positions in the Shares or underlying Shares which fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO as recorded in the register required to be kept by the Company pursuant to Section 366 of the SFO:

|    |   |   |   |     |
|----|---|---|---|-----|
|    | v |   | u | u   |
| XV | 2 | 3 |   | 366 |
|    |   |   | { |     |

---

| Name | Capacity/Nature of interest | Number of H Shares <sup>(1)</sup> | Approximate percentage in our total share capital |
|------|-----------------------------|-----------------------------------|---|
| ' ²  |                             | ...VA©°bÁú eQI`”°                 |   |



| Name  | Capacity/Nature of interest                       | Number of H Shares <sup>(1)</sup> | Approximate percentage in our total share capital & p l < X |
|---|---|-----------------------------------|---|
| ‘ ¼   | ... J Æ B Ì /                                     | H p p ... p Ž <sup>(1)</sup>      | Y ? Ö õ ± â   |
| YANG Lei                                    | Interest in controlled corporation <sup>(6)</sup> | 38,857,460 (L)                    | 8.35%   |
| Shannan Yanshi Venture Investment Co., Ltd. | Interest in controlled corporation <sup>(6)</sup> | 38,857,460 (L)                    | 8.35%   |
| WANG Jinghui                                | Interest in controlled corporation <sup>(6)</sup> | 38,857,460 (L)                    | 8.35%   |
| HU Qiaohong                                 | Beneficial owner                                  | 32,978,255 (L)                    | 7.08%   |

- (1) (2) See Corporate Governance and Other Information Interests and Short Positions of the Directors, Supervisors and the Chief Executive of Our Company in the Shares, Underlying Shares and Debentures of Our Company and Its Associated Corporations in this interim report for more information.
- (3) Ms. Xue is the spouse of Mr. Zheng. Accordingly, they are deemed to be interested in the same number of Shares of each other for the purpose of the SFO.
- (4) Xiamen Guangyao Tianxiang Investment Co., Ltd. is the sole general partner of Guangyao Tianxiang LP and is therefore deemed to be interested in the Shares held by Guangyao Tianxiang under the SFO.
- (5) The general partner of Xiamen Jinyanlai LP is Wang Junjie, who is therefore deemed to be interested in the Shares held by Xiamen Jinyanlai LP under the SFO.
- (6) Beijing Yanshi Investment Management Center (Limited Partnership) is the sole general partner of Hongyan Investment LP. The general partner of Beijing Yanshi Investment Management Center (Limited Partnership) is YANG Lei and the limited partner of Beijing Yanshi Investment Management Center (Limited Partnership) holds more than one-third of its limited partnership interest is Shannan Yanshi Venture Investment Co., Ltd. (a company owned as to 51% by WANG Jinghui and 45% by WANG Yalong). As such, each of Beijing Yanshi Investment Management Center (Limited Partnership), YANG Lei, Shannan Yanshi Venture Investment Co., Ltd., WANG Jinghui and WANG Yalong is deemed to be interested in the Shares held by Hongyan Investment LP under the SFO.



CORPORATE GOVERNANCE AND OTHER INFORMATION  
®!7# ç!ü!1

Save as disclosed above, as of June 30, 2025, the Directors, Supervisors and



(iii) Scheme administration

A management committee has been authorized to act as the scheme administrator to manage the scheme and the related shareholding platform, including but not limited to, formulating and amending detailed implementation documents for the scheme, managing the daily operation of the scheme and related shares, approving the exit and share transfer, determining and explaining terms of the scheme and related matters thereunder and other work as otherwise authorized by the Company. The management committee shall consist of eight members including one team leader who is the chairman of the Company, three deputy team leaders who are the Company's vice chairman, general manager, and chairman of the board of Supervisors, and four team members who are the Company's chief financial officer, board secretary, human resources director and manager of the legal department.

(iv) Maximum number of Shares

A total number of 8,208,320 Shares underlying the Employee Incentive Scheme were issued to Jinyan Tengfei LP for the purpose of the Employee Incentive Scheme, representing approximately 1.76% of the total issued share capital of the Company. As of June 30, 2025, all Shares subject to the Employee Incentive Scheme have been granted to and subscribed by 43 Participants.

(v) Rights and Restrictions Attached to the Limited Partnership Interests in Jinyan Tengfei LP that were Subscribed For

The Company shall establish a limited partnership entity as an employee shareholding platform to hold and manage the Shares under the scheme. The general partner of such entity shall be the person representing and responsible for the management of such entity, including exercising the voting rights attached to the Shares held by Jinyan Tengfei LP, and the limited partners shall not participate in the management. Accordingly, the Company established Jinyan Tengfei LP as the employee shareholding platform, the general partner of which is Mr. Huang and the limited partners of which are grantees under the scheme.

(iii) 公司管理

本公司已授权管理委员会作为该计划的行政人，负责管理该计划及相关持股平台，包括但不限于，制定和修订该计划的详细实施文件，管理该计划的日常运营及相关股份，批准退出和股份转让，确定和解释该计划及相关事项，以及其他经本公司授权的其他工作。管理委员会将由八名成员组成，包括一名团队负责人，即本公司董事长，三名团队副负责人，即本公司副董事长、总经理和监事会主席，以及四名团队成员，即本公司首席财务官、董事会秘书、人力资源总监和法务部门负责人。

(iv) 股份总数

共有 8,208,320 股与员工激励计划相关的股份由锦炎腾飞 LP 发行，用于员工激励计划的目的，代表公司总发行股本的约 1.76%。截至 2025 年 6 月 30 日，所有与员工激励计划相关的股份均已授予并由 43 名参与者认购。

(v) 拟认购锦炎腾飞 LP 有限合伙权益所附带的权利和限制

公司应设立有限合伙实体作为员工持股平台，用于持有和管理该计划下的股份。该实体的普通合伙人应为负责代表和管理该实体的个人，包括行使附着于锦炎腾飞 LP 持有的股份上的投票权，而有限合伙人不应参与该实体的管理。因此，公司设立了锦炎腾飞 LP 作为员工持股平台，其普通合伙人由黄先生担任，有限合伙人由该计划下的权益授予对象担任。



All the grantees shall be entitled to all the economic interests relating to their respective limited partnership interests in Jinyan Tengfei LP that were subscribed for, except that the limited partnership interests in Jinyan Tengfei LP that were subscribed for shall be subject to certain transfer and disposal restrictions, including: (i) the completion of a qualified listing; (ii) the expiry of the lock-up period as required by the CSRC (where applicable); and (iii) 36 months commencing from the date of implementation of the scheme. In addition, each grantee who is Director, Supervisor or senior management of the Company shall retain at least 10% of the total Shares subscribed by him/her under the scheme during his/her term of employment, to avoid short selling and control the risk.

u  
 u (i) z (ii)  
 — z  
 (iii) 36 w  
 u v  
 10%u  
 w

In the event that the relevant grantees conduct material malfeasance, violate the lock-up requirements, take action materially adversely affect the Group or conduct competitive business without the approval of the Company, such limited partnership interests in Jinyan Tengfei LP that were subscribed for shall be unconditionally sold to other limited partners or third parties designated by the scheme administrator at the price calculated based on the following calculation methods, whichever is lower and deducting the taxes and administrative expenses accrued per share: (a) the actual subscription price paid by such grantee; or (b) the most recent and valid fair value assessed.

v v  
 u  
 u { (a)  
 z (b)  
 w

In the other events, the sales price shall be determined with reference to the principal above and such shall not be higher than the price calculated based on the following calculation methods, whichever is higher and deducting the taxes and administrative expenses accrued per share: (a) the actual subscription price paid by such grantee plus interests of commercial banks in the same period; or (b) the most recent and valid fair value assessed or the market trading price.

u  
 u { (a)  
 z (b)  
 w



(vi) Details of the Awards granted

(vi) 授予奖励的情况

Below is the list of the grantees under the Employee Incentive Scheme that are entitled to the limited partnership interests in Jinyan Tengfei LP that were subscribed for as of June 30, 2025:

u

{

| Name   | Role  | Date of grant     | Number of Shares <sup>2)</sup> | Approximate percentage of shareholding as of June 30, 2025 |
|--|---|-------------------|--------------------------------|--|
| 姓名   | 职位  | 授予日期              | 股数 (1)                         | 持股比例   |
| <i>Directors, Supervisors, Senior Management and Other Connected Persons</i> |   |                   |                                |  |
| Weng Huizhen   | Deputy general manager                                    | December 26, 2020 | 425,191                        | 0.09%  |
| Chen Zhigao  | Chief financial officer                                   | December 26, 2020 | 425,191                        | 0.09%  |
| Huang Danyan   | Executive Director and deputy general manager             | December 26, 2020 | 425,191                        | 0.09%  |
| Li Liangjie  | Deputy general manager                                    | December 26, 2020 | 425,191                        | 0.09%  |
| Fan Qunyan   | Deputy general manager                                    | December 26, 2020 | 425,191                        | 0.09%  |
| Wei Wei  | Supervisor  | December 26, 2020 | 299,604                        | 0.06%  |
| Zhang Ning   | Supervisor  | December 26, 2020 | 174,837                        | 0.04%  |
| Xiong Ting   | Board secretary and joint company secretary               | December 26, 2020 | 174,837                        | 0.04%  |
| Mr. Huang  | Executive Director and chairman of the Board of Directors | December 26, 2020 | 3,283                          | 0.001%   |
| Subtotal   |   |                   | 2,778,516                      | 0.60%  |
| <i>Other grantees</i>  |   |                   |                                |  |
| 34 grantees  | Employees   | December 26, 2020 | 5,429,804                      | 1.17%  |

Notes:

{

(1) For illustrating the indirect interests of grantees in our Company, the number of Shares are presented and calculated by multiplying their respective percentage of limited partnership interests in Jinyan Tengfei LP (in two decimal places) by the total number of Shares held by Jinyan Tengfei LP.

(1)

u

w



All the limited partnership interests in Jinyan Tengfei LP granted under the Employee Incentive Scheme are subject to certain transfer and disposal restrictions set out above. No grant of the limited partnership interests in Jinyan Tengfei LP under the Employee Incentive Scheme has caused any dilution of the shareholding of our Shareholders after the Listing.

## H SHARE INCENTIVE SCHEME

The H Share Incentive Scheme was approved and adopted by the Company on March 25, 2024. The terms of the H Share Incentive Scheme are subject to the provisions of Chapter 17 of the Listing Rules. Summary of major terms of the H Share Incentive Scheme are as follows:

### (i) Purposes of H Share Incentive Scheme

The purposes of the H Share Incentive Scheme include (a) promoting the achievement of long-term sustainable development and performance goals of the Company, (b) closely aligning the interests of the grantees with those of the Shareholders, investors and the Company to enhance the cohesion of the Company and to facilitate the maximization of the value of the Company, and (c) improving the Company's incentive mechanism to attract, motivate and retain Directors, Supervisors, senior management, core employees and service providers who have made outstanding contributions to the sustainable operation, development and long-term growth of the Company.

### (ii) Participants of H Share Incentive Scheme

Eligible participants who may participate in the H Share Incentive Scheme include: (a) any Director (excluding independent non-executive Director), Supervisor, senior management or employee of the Group; and (b) any service provider as the Board deems fit.

A person shall not be considered as an eligible participant if, at the Grant Date, he/she: (a) is an independent non-executive Director; (b) has been publicly censured or declared as an ineligible candidate by securities regulatory institutions in the last 12 months; (c) has been imposed with administrative penalties by securities regulatory institutions in the last 12 months due to material non-compliance of laws or regulations; (d) is prohibited from acting as a Director, Supervisor or a member of the senior management of the Company as required by the PRC Company Law or the Listing Rules; (e) is prohibited from participating in the Scheme as required by laws and regulations; (f) has committed other material violation of relevant requirements of the Group or caused material damage to the interest of the Group as determined by the Board; or (g) any other circumstances prescribed by the Board for the purpose of safeguarding the Group's interests and ensuring the Group's compliance with applicable laws and regulations relating to the operation of the H Share Incentive Scheme.

w u  
w

## H p ç , Œ

H  
wH  
wH  
{

### (i) Hp ç , Œ Y f Y

H { (a)  
u (b)  
v  
u u  
u (c)  
u v  
v v v  
w

### (ii) Hp ç , Œ Y ~ [ {

H {  
(a) — z (b)  
~v v z w  
{ (a) z (b)  
12 z (c) 12  
z (d)  
u  
v z (e)  
z (f)  
z  
(g) H w



(iii) Scheme Limit

In any event, the maximum number of Target Shares corresponding to the Trust Units which may be granted under the H Share Incentive Scheme shall not exceed 5% of the Company's total Shares in issue as at the adoption of the H Share Incentive Scheme (the Scheme Limit), which was 23,275,000 H Shares.

(iv) Limit for each participant

None of the grantees shall be granted with an aggregate of more than 1% of the Company's total Shares in issue in any 12-month period up to and including the Grant Date.

(v) Grant of Trust Units

Subject to the terms and conditions of the H Share Incentive Scheme, the Board and/or the Delegatee(s) may at their absolute discretion and on such terms and conditions as the Board and/or the Delegatee(s) thinks fit, grant the Trust Units to any eligible participant at the Grant Price, which shall be determined by the Board and/or the Delegatee(s). The consideration shall be paid by the relevant grantee when the Trust Units are vested.

After the Board and/or the Delegatee(s) has decided to make a grant of Trust Units to any grantee, the Company shall issue an Award Letter to such grantee, which should set out details of the grant, including but not limited to the name of the grantee, the Trust Units granted, the vesting criteria and conditions, the vesting date, Grant Price and other terms and conditions to be determined by the Board and/or the Delegatee(s) that are not inconsistent with the H Share Incentive Scheme. The grantee shall confirm in writing his acceptance of such grant.

(vi) Vesting of the Trust Units

Subject to all applicable laws, rules or regulations, the Board and/or the Delegatee(s) will determine the vesting criteria and conditions and the vesting periods for the Trust Units to be granted to each grantee pursuant to the H Share Incentive Scheme. The details of the vesting conditions and terms shall be determined by the Board and/or the Delegatee(s) from time to time with reference to, among others, the business performance and financial position of the Company and the prevailing market conditions and shall be set out in the Award Letter.

(iii) 總數

u H u  
H  
5%<sup>2</sup> 總數<sup>3</sup> u  
23,275,000 H w

(iv) 每位參與者

— 12  
u 1% w

(v) 授出信託單位

H u u  
u w w  
w

(vi) 信託單位的歸還

v H u  
w  
— 12  
w u



Within a reasonable time after the vesting conditions and schedule have been reached, fulfilled, satisfied or waived and before the date of vesting, the Board or its Delegatee(s) shall send the vesting notice to each of the relevant grantees. The vesting notice will confirm, among others, the extent to which the vesting conditions and schedule have been reached, fulfilled, satisfied or waived, and the number of Trust Units and Target Shares to be vested for that relevant vesting period.

v v  
w — -  
v v  
w

If a grantee satisfies the vesting conditions applicable to the grant of such Trust Units and accepts the vesting of relevant Trust Units, such grantee shall confirm in writing for his acceptance and fully pay the relevant Grant Price either in cash or by deduction of such number of Shares equivalent to the Grant Price, to vest the relevant Trust Units.

u  
u w

After the relevant Trust Units are duly vested in accordance with the aforementioned procedures, subject to compliance with the relevant laws, regulations, rules and regulatory documents of the places where the Company is established and listed, as well as the articles of association of the Company, the Trustee shall allocate and dispose the Target Shares which corresponds to the Trust Units vested in the grantees in accordance with the instruction of the grantees pursuant to the H Share Incentive Scheme.

u  
v v u H  
w

(vii) Grant Price

(vii) → š ø

The grant price of each Target Share underlying the Trust Unit shall be determined by the Board and/or the Delegatee(s).

w

(viii) Remaining life of the H Share Incentive Scheme and (viii) H p ç , Œ ð q , " ç ï - . !  
outstanding Trust Units Ä a B Æ ... X

The H Share Incentive Scheme will be valid and effective for a period of ten years commencing on March 25, 2024.

H  
w

For further information of the H Share Incentive Scheme and related information, please refer to the announcement of the Company dated January 12, 2024 and the circular of the Company dated March 7, 2024.

H u  
w





CORPORATE GOVERNANCE AND OTHER INFORMATION  
 7 # ç ! ü ! 1

| Category/<br>Name of Grantee | Date of Grant | Purchase Price | Vesting Period   | Number of<br>unvested H Shares<br>underlying<br>the Trust Units<br>as of January 1,<br>2025 | Granted<br>during the<br>Reporting<br>Period | Vested<br>during the<br>Reporting<br>Period | Lapsed during<br>the Reporting<br>Period | Number of<br>unvested H Shares<br>underlying<br>the Trust Units<br>as of June 30,<br>2025 | Weighted average<br>closing price of<br>the H Shares<br>before vesting |
|------------------------------|---------------|----------------|--|---|--|---|--|---|--|
|                              |               |                |  | Ü ZgZžĒ<br>SÜSÜJánY<br>!ÄaBÆ...X<br>'ë HppŽ   | S,«<br>-š                                    | S,«<br>än                                   | S,«0Ö                                    | Ü ZgZžĒ<br>-ÜgdÜJánY<br>!ÄaBÆ...X<br>'ë HppŽ  | HpánÄY<br>Æ;ix9  |
| Mr. Zheng                    | December 2024 | HK\$4.85       | The Trust Units shall vest in three tranches of 40% in July 2026, 30% in July 2027 and 30% in July 2028, respectively. | 332,500   |  |   |  | 332,500   | N/A  |
| Li Youquan                   | December 2024 | HK\$4.85       | The Trust Units shall vest in three tranches of 40% in July 2026, 30% in July 2027 and 30% in July 2028, respectively. | 997,500   |  |   |  | 997,500   | N/A  |
| HUANG Danyan                 | December 2024 | HK\$4.85       | The Trust Units shall vest in three tranches of 40% in July 2026, 30% in July 2027 and 30% in July 2028, respectively. | 166,250   |  |   |  | 166,250   | N/A  |
| LIU Zhen                     | December 2024 | HK\$4.85       | The Trust Units shall vest in three tranches of 40% in July 2026, 30% in July 2027 and 30% in July 2028, respectively. | 166,250   |  |   |  | 166,250   | N/A  |
| WANG Yalong                  | December 2024 | HK\$4.85       | The Trust Units shall vest in three tranches of 40% in July 2026, 30% in July 2027 and 30% in July 2028, respectively. | 166,250   |  |   |  | 166,250   | N/A  |



| Category/<br>Name of Grantee             | Date of Grant | Purchase Price | Vesting Period   | Number of<br>unvested H Shares<br>underlying<br>the Trust Units<br>as of January 1,<br>2025 | Granted<br>during the<br>Reporting<br>Period | Vested<br>during the<br>Reporting<br>Period | Lapsed during<br>the Reporting<br>Period | Number of<br>unvested H Shares<br>underlying<br>the Trust Units<br>as of June 30,<br>2025 | Weighted average<br>closing price of<br>the H Shares<br>before vesting |
|--|---------------|----------------|--|---|--|---|--|---|--|
|  |               |                |  | Ú Zg Zž Ě<br>S Ū S Ū J á n Y<br>! Ā a B Ą Ę ... X<br>' ē H p p Ž                            | S, «<br>- š                                  | S, «<br>ā n                                 | S, « 0 Ō                                 | Ú Zg Zž Ě<br>- Ū g d Ū J á n Y<br>! Ā a B Ą Ę ... X<br>' ē H p p Ž                        | H p ā n Ā Y<br>Ą Ę ; i x 9   |
| ZHENG Feng                               | December 2024 | HK\$4.85       | The Trust Units shall vest in three tranches of 40% in July 2026, 30% in July 2027 and 30% in July 2028, respectively. | 166,250   |  |   |  | 166,250   | N/A  |
|  |               | 4.85           | u<br>v<br>40%v 30% 30%w  |   |  |   |  |   |  |
| HUANG Junhao <sup>(1)</sup>              | December 2024 | HK\$4.85       | The Trust Units shall vest in three tranches of 40% in July 2026, 30% in July 2027 and 30% in July 2028, respectively. | 133,000   |  |   |  | 133,000   | N/A  |
|  |               | 4.85           | u<br>v<br>40%v 30% 30%w  |   |  |   |  |   |  |
| XUE Fenghong <sup>(2)</sup>              | April 2025    | HK\$4.85       | The Trust Units shall vest in three tranches of 40% in July 2026, 30% in July 2027 and 30% in July 2028, respectively. |   | 133,000                                      |   |  | 133,000   | N/A  |
|  |               | 4.85           | u<br>v<br>40%v 30% 30%w  |   |  |   |  |   |  |
| LI Jiangtao <sup>(3)</sup>               | April 2025    | HK\$4.85       | The Trust Units shall vest in three tranches of 40% in July 2026, 30% in July 2027 and 30% in July 2028, respectively. |   | 133,000                                      |   |  | 133,000   | N/A  |
|  |               | 4.85           | u<br>v<br>40%v 30% 30%w  |   |  |   |  |   |  |
| <i>Employees</i>                         |               |                |  |   |  |   |  |   |  |
| 62 employees in aggregate <sup>(4)</sup> | December 2024 | HK\$4.85       | The Trust Units shall vest in three tranches of 40% in July 2026, 30% in July 2027 and 30% in July 2028, respectively. | 3,824,000   |  |   |  | 3,824,000   | N/A  |
|  |               | 4.85           | u<br>v<br>40%v 30% 30%w  |   |  |   |  |   |  |



CORPORATE GOVERNANCE AND OTHER INFORMATION  
 7 # 2 1 1 1

| Category/<br>Name of Grantee                   | Date of Grant | Purchase Price | Vesting Period   | Number of<br>unvested H Shares<br>underlying<br>the Trust Units<br>as of January 1,<br>2025 | Granted<br>during the<br>Reporting<br>Period | Vested<br>during the<br>Reporting<br>Period | Lapsed during<br>the Reporting<br>Period | Number of<br>unvested H Shares<br>underlying<br>the Trust Units<br>as of June 30,<br>2025 | Weighted average<br>closing price of<br>the H Shares<br>before vesting |
|--|---------------|----------------|--|---|--|---|--|---|--|
| Seven employees<br>in aggregate <sup>(4)</sup> | April 2025    | HK\$4.85       | The Trust Units shall vest in three tranches of 40% in July 2026, 30% in July 2027 and 30% in July 2028, respectively. |   | 649,000                                      |   |  | 649,000   | N/A  |

Notes:

- (1) HUANG Junhao is the son of Mr. Huang.
- (2) XUE Fenghong is the sister-in-law of ZHENG Wenbin, an executive Director and the vice chairman of the Board.
- (3) LI Jiangtao is the nephew of LI Youquan, an executive Director and the general manager of the Company.
- (4) None of the grantees is a Director, a chief executive, or a substantial shareholder of the Company, or an associate of any of them.

Save as disclosed above, no Trust Unit has been granted under the H Share Incentive Scheme during the Reporting Period.

INTERIM DIVIDEND

The Board resolved not to declare any interim dividend for the six months ended June 30, 2025.

COMPLIANCE WITH THE CG CODE

The Company's corporate governance practices are based on the principles and code provisions as set out in the CG Code and the Company has adopted the CG Code as its own code of corporate governance.

During the Reporting Period, the Company had complied with all the applicable code provisions as set out in the CG Code.



## COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its own code of conduct regarding the transactions of securities of the Company by its directors, supervisors and the relevant employees who would likely possess inside information of the Company. Specific enquiry has been made to all directors and supervisors of the Company and all of them have confirmed that they have complied with the Model Code during the six months ended June 30, 2025.

## CHANGES OF INFORMATION OF DIRECTORS AND SUPERVISORS

During the six months ended June 30, 2025 and up to the date of this report, there were no changes to the information of Directors and Supervisors.

## CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE LISTING RULES

As of June 30, 2025, the Company had no other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

## AUDIT COMMITTEE AND REVIEW OF INTERIM FINANCIAL RESULTS

The Audit Committee has been established in compliance with Rules 3.21 and 3.22 of the Listing Rules with written terms of reference in compliance with the CG Code. The primary responsibilities of the Audit Committee are to review and monitor the financial reporting, risk management and internal control systems of the Company and to assist the Board to fulfill its responsibilities over the audit.

As of the date of this interim report, the Audit Committee comprises three independent non-executive Directors, namely, Mr. CHEN Aihua, Mr. XIAO Wei and Mr. LAM Yiu Por, and Mr. CHEN Aihua serves as the chairman of the Audit Committee.

m Â Ç N t ø z \_ Â Æ

v

w  
u

w

è + ç 9 + Y Ø

u

w

ì ½ j 9 • Æ ~ 5 f Þ £ a ,

u

13.20v 13.21 13.22 u  
w

2 %o p 6 ç 2 a • , ì 8 6

3.21 3.22

u  
w

v

u

w

u

u

v

u

w



The Audit Committee has reviewed and confirmed the accounting principles and policies adopted by the Group and discussed the auditing, internal control and financial reporting matters of the Group. The interim results of the Group for the six months ended June 30, 2025 have also been reviewed by the Audit Committee.

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity*, issued by the Hong Kong Institute of Certified Public Accountants (HKICPA).

### PURCHASE, SALE OR REDEMPTION OF THE LISTED SECURITIES OF THE COMPANY

Neither the Company nor its subsidiary had purchased, sold or redeemed any of the Company's listed securities (including the sale of Treasury Shares (as defined under the Listing Rules), if any) during the Reporting Period. As at June 30, 2025, the Company did not hold any Treasury Shares.

### ARRANGEMENT TO PURCHASE SHARES OR DEBENTURES

Save as disclosed in this report, at no time during six months ended June 30, 2025 was the Company or its subsidiaries a party to any arrangement that would enable the Directors or Supervisors to acquire benefits by means of acquisition of shares in, or debentures of, the Company or any other body corporates, and none of the Directors, Supervisors or any of their spouses or children under the age of 18 were granted any right to subscribe for the equity or debt securities of the Company or any other body corporates or had exercised any such right.

### DIRECTORS RESPONSIBILITIES FOR FINANCIAL REPORTING IN RESPECT OF THE FINANCIAL STATEMENTS

The Directors acknowledge their responsibilities for preparing the financial statements of the Company for the six months ended June 30, 2025.

u v  
w

w

u  
—  
3 - a « 2410 2  
3 w

... o e / Đ Û « I ® ! j 9 Ç N

u v  
— — — w  
u w

... o p ... Đ À N Y Ä °

u  
u  
u v 18  
u  
w

è + Á ì Œ Y ì S a ,

w



The Board is responsible for presenting a balanced, clear and understandable assessment of annual and interim reports, inside information announcements and other disclosures required under the Listing Rules and other statutory and regulatory requirements. The management has provided to the Board such explanation and information as are necessary to enable the Board to carry out an informed assessment of the Company's financial statements, which are put to the Board for approval. The management provides all members of the Board with monthly updates on the Company's performance, positions and prospects.

## EMPLOYEES, TRAINING AND REMUNERATION POLICIES

As of June 30, 2025, we had 1,590 employees. The labor costs including Directors and Supervisors emoluments and share-based payment expenses were approximately RMB148.78 million for the six months ended June 30, 2025.

Our employees' compensation includes basic salary, performance-based cash bonuses and other incentives. We determine our employees' compensation based on each employee's performance, qualifications, position and seniority. In order to improve the Company's incentive mechanism, retain key employees and promote the sustainable development of the Company's business, the Board proposed the H Share Incentive Scheme to the Shareholders' general meeting for consideration to incentivize the management personnel and core technical employees who play important roles in the Company's operating results and future development. The H Share Incentive Scheme was approved and adopted on March 25, 2024. For the details of the H Share Incentive Scheme and related information, please refer to the announcement of the Company dated January 12, 2024 and the circular of the Company dated March 7, 2024.

We recognize the importance of keeping the Directors updated with the latest information of duties and obligations of a director of a company whose shares are listed on the Stock Exchange and the general regulatory and environmental requirements for such listed company. To meet this goal, we are committed to the continuing education and development of the Directors.

v  
v w u  
u w v  
w

## † p e C Å ĩ Z G A

u 1,590  
w  
u  
148.78 w  
v  
w v  
v w  
u u H  
u w H  
H u w  
w

u  
w  
u w





The table below sets out the planned and actual applications of the net proceeds up to June 30, 2025.

w

|   | Net proceeds<br>from the<br>Global Offering | Equivalent<br>to RMB | Utilization<br>as of<br>June 30, 2025 | Unutilized<br>proceeds as of<br>June 30, 2025 |
|---|---|----------------------|---------------------------------------|---|
|   | HK\$  | RMB                  | RMB                                   | RMB   |
|   | (HKD in millions)                           | (RMB in millions)    | (RMB in millions)                     | (RMB in millions)                             |
|   | €   | €                    | €                                     | €   |
| Research and development activities to expand our product portfolio and enrich our product features | 25.6  | 23.3                 | 20.5                                  | 2.8   |
| Expand and consolidate our sales network  | 64.1  | 58.3                 | 54.7                                  | 3.6   |
| Strengthen our brand building and marketing promotion efforts                                       | 38.5  | 35.0                 | 35.0                                  |   |
| Strengthen our supply chain management capabilities   | 89.8  | 81.6                 | 81.6                                  |   |
| Strengthen our digital infrastructure   | 12.8  | 11.7                 | 10.1                                  | 1.6   |
| Working capital and other general corporate purposes  | 25.6  | 23.3                 | 23.3                                  |   |
| <b>Total</b>  | <b>256.46</b>                               | <b>233.21</b>        | <b>225.2</b>                          | <b>8.0</b>                                    |

To the extent that the net proceeds have not been immediately utilized, the balance has been deposited with banks. The Board currently do not expect to change the intended use of net proceeds as previously disclosed in the Prospectus, and expects full utilization of the net proceeds raised from the Global Offering by December 31, 2028, subject to changes in light of the Company's evolving business needs and changing market conditions.

u w  
u  
u w



## EVENTS AFTER THE REPORTING PERIOD

As of the date of this interim report, save as disclosed in the notes to the financial statements in this interim report, there has been no significant event since the end of the Reporting Period that is required to be disclosed by the Company.

By Order of the Board  
Xiamen Yan Palace Bird Nest Industry Co., Ltd.  
HUANG Jian  
*Chairman and Executive Director*

Hong Kong, August 29, 2025

S, + °

u  
u  
w

~ ò ~ ò J \* 8 p ... Þ " ® !

»

u



Review report to the board of directors  
of Xiamen Yan Palace Bird's Nest Industry Co., Ltd.  
(Incorporated in the People's Republic of China with limited liability)

## INTRODUCTION

We have reviewed the interim financial report set out on pages 50 to 92, which comprise the consolidated statement of financial position of Xiamen Yan Palace Bird's Nest Industry Co., Ltd. (the Company) as of 30 June 2025 and the related consolidated statement of profit or loss, consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and condensed consolidated cash flow statement for the six-month period then ended, and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of an interim financial report to be in compliance with the relevant provisions thereof and International Accounting Standard 34, *Interim Financial Reporting* as issued by the International Accounting Standards Board. The directors are responsible for the preparation and presentation of this interim financial report in accordance with International Accounting Standard 34.

Our responsibility is to express a conclusion, based on our review, on this interim financial report and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

## SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity* as issued by the Hong Kong Institute of Certified Public Accountants. A review of interim financial report consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.

ç ~ ò ~ ò J \* 8 p ... P " @ !  
è + 6 ~ 2 a S

ï

50 92  
u 2 3  
v  
v w a  
« u  
a « 34  
w a  
« 34 w  
u  
u w u  
w  
u w

2 a í

a  
« 2410  
w u  
w u  
w u w



## CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial report as at 30 June 2025 is not prepared, in all material respects, in accordance with International Accounting Standard 34 *Interim Financial Reporting*.

u  
u  
a  
« 34 w

KPMG  
*Certified Public Accountants*  
8th Floor, Prince s Building  
10 Chater Road  
Central, Hong Kong  
29 August 2025

- õ þ 6 a + Ô

10  
8



# CONSOLIDATED STATEMENT OF PROFIT OR LOSS



For the six months ended 30 June 2025 – unaudited  
(Expressed in Renminbi)–

€

|                                    |           | Six months ended 30 June |           |           |
|------------------------------------|-----------|--------------------------|-----------|-----------|
|                                    |           | 2025                     | 2024      |           |
|                                    |           | Z g Z ž Ě                |           |           |
|                                    |           | RMB000                   | RMB 000   |           |
|                                    |           | [ O Æ w ©                |           |           |
|                                    |           | Note                     |           |           |
| Revenue                            | × ]       | 3                        | 1,014,581 | 1,059,304 |
| Cost of sales                      |           |                          | (487,051) | (545,505) |
| Gross profit                       | ã ;       |                          | 527,530   | 513,799   |
| Other net income                   |           | 4                        | 6,319     | 7,973     |
| Selling and distribution expenses  |           |                          | (333,484) | (365,272) |
| Administrative expenses            |           |                          | (66,582)  | (62,604)  |
| Research and development expenses  |           |                          | (11,349)  | (12,358)  |
| Impairment loss on goodwill        |           | 9                        | (9,179)   |           |
| Profit from operations             | ¼ ; —     |                          | 113,255   | 81,538    |
| Finance costs                      |           | 5(a)                     | (3,206)   | (3,532)   |
| Profit before taxation             | ð ü Ã ; — | 5                        | 110,049   | 78,006    |
| Income tax                         |           | 6(a)                     | (32,598)  | (17,961)  |
| Profit for the period              | , « ; —   |                          | 77,451    | 60,045    |
| Attributable to:                   | Đ & j     |                          |           |           |
| Equity shareholders of the Company |           |                          | 75,261    | 58,080    |
| Non-controlling interests          |           |                          | 2,190     | 1,965     |
| Profit for the period              | , « ; —   |                          | 77,451    | 60,045    |
| Earnings per share                 | Ê p ® ;   |                          |           |           |
| Basic and diluted (RMB)            | — -       | 7                        | 0.16      | 0.12      |

The notes on pages 57 to 92 form part of this interim financial report. Details of dividends payable to equity shareholders of the Company are set out in note 16(a).

57 92  
w  
16(a)w



# CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME



For the six months ended 30 June 2025 – unaudited

(Expressed in Renminbi)–

|   | Six months ended 30 June |         |
|---|--------------------------|---------|
|   | 2025                     | 2024    |
|   | Z g Z ž Ě                | RMB 000 |
|   | [ O Æ w ©                | RMB 000 |
| Profit for the period , « ; —   | 77,451                   | 60,045  |
| Other comprehensive income for the period , « I ü Ć & x B Ć Ô ð ü ° ħ<br>(after tax and reclassification adjustments) ± ó Æ •           |                          |         |
| Items that will not be reclassified to profit or loss: {  |                          |         |
| Equity investments at fair value through other comprehensive income ( FVOCI ) net movement in fair value reserves (non-recycling) — ì - | (7,078)                  |         |
| Items that are or may be reclassified subsequently to profit or loss: {   |                          |         |
| Exchange differences on translation of financial statements of operations outside Chinese Mainland                                      | 51                       |         |
| Other comprehensive income for the period , « I ü Ć & x B   | (7,027)                  |         |
| Total comprehensive income for the period , « Ć & x B < X   | 70,424                   | 60,045  |
| Attributable to: Đ & j  |                          |         |
| Equity shareholders of the Company  | 68,211                   | 58,080  |
| Non-controlling interests   | 2,213                    | 1,965   |
| Total comprehensive income for the period , « Ć & x B < X   | 70,424                   | 60,045  |

The notes on pages 57 to 92 form part of this interim financial report.

57 92  
w



# CONSOLIDATED STATEMENT OF FINANCIAL POSITION

■

At 30 June 2025 – unaudited  
(Expressed in Renminbi)–

ë

|  |       | Note  | At<br>30 June<br>2025<br>RMB000<br>[ O Æ w © | At<br>31 December<br>2024<br>RMB 000 |
|--|-------|-------|--|--------------------------------------|
| Non-current assets   | ç t * |       |  |                                      |
| Property, plant and equipment  | v     | 8     | 272,646                                      | 282,421                              |
| Intangible assets  |       |       | 3,640  | 1,982                                |
| Goodwill   |       | 9     | 67,986                                       | 77,165                               |
| Equity securities designated at FVOCI                                      |       | 10    | 27,874                                       | 35,948                               |
| Financial assets measured at fair value through<br>profit or loss ( FVPL ) |       |       | 991  | 991                                  |
| Deferred tax assets  |       |       | 63,014                                       | 51,227                               |
| Other non-current assets   |       |       | 26,273                                       | 23,365                               |
|  |       |       | 462,424                                      | 473,099                              |
| Current assets   | t *   |       |  |                                      |
| Inventories  |       | 11    | 197,598                                      | 353,198                              |
| Trade and other receivables  |       | 12(a) | 95,898                                       | 163,656                              |
| Prepayments  |       | 12(b) | 75,713                                       | 75,996                               |
| Prepaid taxes  |       |       | 3,446  | 157                                  |
| Cash and cash equivalents  |       | 13    | 518,294                                      | 420,508                              |
|  |       |       | 890,949                                      | 1,013,515                            |
| Current liabilities  | t Å   |       |  |                                      |
| Trade and other payables   |       | 14    | 199,323                                      | 271,050                              |
| Contract liabilities   |       |       | 238,835                                      | 254,075                              |
| Lease liabilities  |       |       | 29,830                                       | 25,267                               |
| Other current liabilities  |       |       | 29,706                                       | 32,348                               |
| Current taxation   |       |       | 17,380                                       | 28,732                               |
|  |       |       | 515,074                                      | 611,472                              |



## CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 30 June 2025 – unaudited

(Expressed in Renminbi)

€

|   |   | At<br>30 June<br>2025 | At<br>31 December<br>2024 |
|---|---|-----------------------|---------------------------|
|   |   | RMB000                | RMB000                    |
| Non-current liabilities   |   |                       |                           |
| Lease liabilities   |   | 96,391                | 105,048                   |
| Dividend payables   |   | 1,393                 |                           |
| Deferred tax liabilities  |   | 493                   | 1,850                     |
|   |   | 98,277                | 106,898                   |
| <b>NET ASSETS</b>   | * | <b>740,022</b>        | <b>768,244</b>            |
| <b>CAPITAL AND RESERVES</b>                                     |   |                       |                           |
| Share capital   |   | 93,100                | 93,100                    |
| Reserves  |   | 625,163               | 652,642                   |
| Total equity attributable to equity shareholders of the Company |   | 718,263               | 745,742                   |
| Non-controlling interests                                       |   | 21,759                | 22,502                    |
| <b>TOTAL EQUITY</b>   |   | <b>740,022</b>        | <b>768,244</b>            |

Approved and authorised for issue by the board of directors on 29 August 2025.

w

Huang Jian  
»  
*Chairman and Executive Director*

Zheng Wenbin  
M Ö ö  
*Vice Chairman and Executive Director*

The notes on pages 57 to 92 form part of this interim financial report.

57 92

w



# CONSOLIDATED STATEMENT OF CHANGES IN EQUITY



For the six months ended 30 June 2025 – unaudited  
(Expressed in Renminbi)–

€

Attributable to equity shareholders of the Company

|   | Note  | Share capital   | Share premium    | Shares held for employee incentive scheme | Statutory reserve | Fair value reserve (non-recycling) | Exchange reserve | Retained profits | Total     | Non-controlling interests | Total equity |
|---|---|-----------------|------------------|---|-------------------|------------------------------------|------------------|------------------|-----------|---------------------------|--------------|
|   |   | RMB 000         | RMB 000          | RMB 000                                   | RMB 000           | RMB 000                            | RMB 000          | RMB 000          | RMB 000   | RMB 000                   | RMB 000      |
|   |   | (Note 16(b)(i)) | (Note 16(b)(ii)) | (Note 16(b)(iii))                         | (Note 16(b)(iv))  | (Note 16(b)(v))                    | (Note 16(b)(vi)) |                  |           |                           |              |
|   |   | – 16(b)(i)      | – 16(b)(ii)      | – 16(b)(iii)                              | – 16(b)(iv)       | – 16(b)(v)                         | – 16(b)(vi)      |                  |           |                           |              |
| Balance at 1 January 2024   | δ Z g Z, È S Û S Û Y q                      | 93,100          | 433,389          |   | 75,869            |                                    |                  | 167,313          | 769,671   | 27,256                    | 796,927      |
| Changes in equity for the six months ended 30 June 2024:                        | Ú Z g Z, È - Û g d Û ß - H Û Æ B j          |                 |                  |   |                   |                                    |                  |                  |           |                           |              |
| Profit and total comprehensive income for the period                            |   |                 |                  |   |                   |                                    |                  | 58,080           | 58,080    | 1,965                     | 60,045       |
| Purchase of own shares under employee incentive scheme                          |   |                 |                  | (7,675)                                   |                   |                                    |                  |                  | (7,675)   |                           | (7,675)      |
| Appropriation to statutory reserve  | 16(b)(iii)                                  |                 |                  |   | 1,370             |                                    |                  | (1,370)          |           |                           |              |
| Dividends approved and paid to the shareholders in respect of the previous year | 16(a)                                       |                 |                  |   |                   |                                    |                  | (100,077)        | (100,077) |                           | (100,077)    |
| Dividends to non-controlling interests  |   |                 |                  |   |                   |                                    |                  |                  |           | (8,640)                   | (8,640)      |
| Balance at 30 June 2024 and 1 July 2024   | δ Z g Z, È - Û g d Û ß Z g Z, È V Û S Û Y q | 93,100          | 433,389          | (7,675)                                   | 77,239            |                                    |                  | 123,946          | 719,999   | 20,581                    | 740,580      |
| Changes in equity for the six months ended 31 December 2024:                    | Ú Z g Z, È d Z Û g d S Û ß - H Û Æ B j      |                 |                  |   |                   |                                    |                  |                  |           |                           |              |
| Profit for the period   |   |                 |                  |   |                   |                                    |                  | 98,215           | 98,215    | 2,170                     | 100,385      |
| Other comprehensive income  |   |                 |                  |   |                   | 13,933                             | (7)              |                  | 13,926    | (6)                       | 13,920       |
| Total comprehensive income  |   |                 |                  |   |                   | 13,933                             | (7)              | 98,215           | 112,141   | 2,164                     | 114,305      |
| Capital injection from non-controlling interests                                |   |                 |                  |   |                   |                                    |                  |                  |           | 485                       | 485          |
| Purchase of own shares under employee incentive scheme                          |   |                 |                  | (86,398)                                  |                   |                                    |                  |                  | (86,398)  |                           | (86,398)     |
| Appropriation to statutory reserve  | 16(b)(iii)                                  |                 |                  |   | 5,228             |                                    |                  | (5,228)          |           |                           |              |
| Dividends to non-controlling interests  |   |                 |                  |   |                   |                                    |                  |                  |           | (728)                     | (728)        |
| Balance at 31 December 2024   | δ Z g Z, È d Z Û g d S Û Y q                | 93,100          | 433,389          | (94,073)                                  | 82,467            | 13,933                             | (7)              | 216,933          | 745,742   | 22,502                    | 768,244      |



## CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2025 – unaudited

(Expressed in Renminbi)–

|  |       | Attributable to equity shareholders of the Company |                  |                                   |                                       |                     |                     |                     |                                  |              |          |         |
|--|-------|--|------------------|-----------------------------------|---------------------------------------|---------------------|---------------------|---------------------|----------------------------------|--------------|----------|---------|
|  |       | 归属于公司权益持有人的权益                                      |                  |                                   |                                       |                     |                     |                     |                                  |              |          |         |
|  | Note  | Shares held  |                  | Share-based<br>payment<br>reserve | Fair value<br>reserve (non-recycling) |                     | Exchange<br>reserve | Retained<br>profits | Non-<br>controlling<br>interests | Total equity |          |         |
|  |       | Share<br>capital                                   | Share<br>premium |                                   | Statutory<br>reserve                  | Exchange<br>reserve |                     |                     |                                  |              | Total    |         |
|  |       | 1 股份   | 2 股份             | 3 股份                              | 4 股份                                  | 5 股份                | 6 股份                | 7 股份                | 8 股份                             | 9 股份         |          |         |
|  |       | 人民币  | 人民币              | 人民币                               | 人民币                                   | 人民币                 | 人民币                 | 人民币                 | 人民币                              | 人民币          |          |         |
|  |       | 千元   | 千元               | 千元                                | 千元                                    | 千元                  | 千元                  | 千元                  | 千元                               | 千元           |          |         |
| Balance at 1 January 2025  |       | 93,100   | 433,389          | (94,073)                          | 82,467                                | 13,933              | (7)                 | 216,933             | 745,742                          | 22,502       | 768,244  |         |
| Changes in equity for the six months ended 30 June 2025:               |       |  |                  |                                   |                                       |                     |                     |                     |                                  |              |          |         |
| Profit for the period  |       |  |                  |                                   |                                       |                     |                     | 75,261              | 75,261                           | 2,190        | 77,451   |         |
| Other comprehensive income   |       |  |                  |                                   | (7,078)                               | 28                  |                     | (7,050)             | 23                               | (7,027)      |          |         |
| Total comprehensive income   |       |  |                  |                                   | (7,078)                               | 28                  |                     | 75,261              | 68,211                           | 2,213        | 70,424   |         |
| Capital injection from non-controlling interests                       |       |  |                  |                                   |                                       |                     |                     |                     |                                  | 1,499        | 1,499    |         |
| Equity-settled share-based transactions                                | 15    |  |                  | 3,942                             |                                       |                     |                     |                     | 3,942                            |              | 3,942    |         |
| Deregistration of a subsidiary   |       |  |                  |                                   | (500)                                 |                     |                     | 500                 |                                  |              |          |         |
| Dividends approved to the shareholders in respect of the previous year | 16(a) |  |                  |                                   |                                       |                     |                     | (99,632)            | (99,632)                         |              | (99,632) |         |
| Dividends to non-controlling interests                                 |       |  |                  |                                   |                                       |                     |                     |                     |                                  | (4,455)      | (4,455)  |         |
| Balance at 30 June 2025  |       | 93,100   | 433,389          | (94,073)                          | 3,942                                 | 81,967              | 6,855               | 21                  | 193,062                          | 718,263      | 21,759   | 740,022 |

The notes on pages 57 to 92 form part of this interim financial report.

57 92

w



# CONDENSED CONSOLIDATED CASH FLOW STATEMENT

€

For the six months ended 30 June 2025 – unaudited  
(Expressed in Renminbi)–

€

|   |                             | Six months ended 30 June |           |
|---|-----------------------------|--------------------------|-----------|
|   |                             | 2025                     | 2024      |
|   |                             | Z g Z ž Ě                | RMB 000   |
|   |                             | [ O Æ w ©                | RMB 000   |
| Operating activities  | ¾ z                         |                          |           |
| Cash generated from operations  |                             | 287,650                  | 130,032   |
| Income tax paid   |                             | (58,015)                 | (26,411)  |
| Net cash generated from operating activities                                | ¾ z Ô { \$ –                | 229,635                  | 103,621   |
| Investing activities  | ³ z                         |                          |           |
| Payment for purchase of property, plant and equipment and intangible assets | v                           | (18,833)                 | (97,623)  |
| Proceeds from disposal of property, plant and equipment                     | v                           | 8                        | 17        |
| Payment for acquisition of financial assets measured at FVPL                |                             | (784,424)                | (434,928) |
| Proceeds from disposal of financial assets measured at FVPL                 |                             | 786,668                  | 435,836   |
| Payment for acquisition of equity securities designated at FVOCI            |                             | (1,363)                  |           |
| Net cash used in investing activities                                       | ³ z Ô \ \$ –                | (17,944)                 | (96,698)  |
| Financing activities  | D z                         |                          |           |
| Capital element of lease rentals paid                                       |                             | (15,983)                 | (15,049)  |
| Interest element of lease rentals paid                                      |                             | (3,206)                  | (3,532)   |
| Payment of listing expenses   |                             |                          | (725)     |
| Payment of shares repurchased for employee incentive scheme                 |                             |                          | (7,675)   |
| Dividends paid to the shareholders  |                             | (91,811)                 | (100,077) |
| Dividends to non-controlling interests                                      |                             | (4,455)                  | (8,640)   |
| Capital injection from non-controlling interests                            |                             | 1,499                    |           |
| Net cash used in financing activities                                       | D z Ô \ \$ –                | (113,956)                | (135,698) |
| Net increase/(decrease) in cash and cash equivalents                        | Š ts ç \$ – J # JE Ç • X    | 97,735                   | (128,775) |
| Cash and cash equivalents at 1 January                                      | ö S Ü S Ú Y \$ – ç \$ – J   | 420,508                  | 537,093   |
| Effect of foreign exchange rate changes                                     | Ò * Y B ¢                   | 51                       | 1,276     |
| Cash and cash equivalents at 30 June  | ö – Ü g d Ú Y \$ – ç \$ – J | 518,294                  | 409,594   |

The notes on pages 57 to 92 form part of this interim financial report.

57 92

w



# NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

24

(Expressed in Renminbi unless otherwise indicated)

u

-

## 1 BASIS OF PREPARATION

This interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with International Accounting Standard ( IAS ) 34, *Interim financial reporting*, issued by the International Accounting Standards Board ( IASB ). It was authorised for issue on 29 August 2025.

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2024 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2025 annual financial statements. Details of any changes in accounting policies are set out in note 2.

The preparation of an interim financial report in conformity with IAS 34 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year-to-date basis. Actual results may differ from these estimates.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Company and its subsidiaries (the Group ) since the 2024 annual financial statements. The condensed consolidated interim financial statements and notes thereon do not include all of the information required for a full set of financial statements prepared in accordance with IFRS Accounting Standards.

## 1 備註

u

2

3

34

2

3

w

w

u

w

2w

34

v

u

v

u

v

w

w

w

u

2

3

u

w

w



## 1 BASIS OF PREPARATION (continued)

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity*, issued by the Hong Kong Institute of Certified Public Accountants (HKICPA). KPMG's independent review report to the Board of Directors is included on pages 48 to 49.

The financial information relating to the financial year ended 31 December 2024 that is included in the interim financial report as comparative information does not constitute the Company's statutory annual consolidated financial statements for that financial year but is derived from those financial statements.

## 2 CHANGES IN ACCOUNTING POLICIES

The Group has applied the amendments to IAS 21, *The effects of changes in foreign exchange rates - Lack of exchangeability* issued by the IASB to this interim financial report for the current accounting period. The amendments do not have a material impact on this interim report as the Group has not entered into any foreign currency transactions in which the foreign currency is not exchangeable into another currency.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

## 1 2024年6月30日止六个月的业绩

u  
-2  
3- a « 2410  
2 3  
w  
48 49 w

u  
u  
w

## 2 6 A

21 u  
ë  
w  
u  
w

w



J ¼ 2 •, Ì S • W

(Expressed in Renminbi unless otherwise indicated) € ð Ö È \$ Ð Ò Ø . d i ø [ O Æ • j •

### 3 x]q±Å S

(a) x]

v

w

3(b) w

{

u

w

u

—

{

10%

w

u

—



### 3 REVENUE AND SEGMENT REPORTING (Continued)

#### (a) Revenue (continued)

The Group has applied the practical expedient in paragraph 121(a) of IFRS15 to its sales contracts for edible bird's nest products that had an original expected duration of one year or less and does not disclose the information related to the aggregated amount of the transaction price allocated to the remaining performance obligations.

#### Seasonality of operations

The Group typically experience lower sales for the first half of the year, compared to the second half of the year, due to the increased demand for its products before and during the holiday seasons and festivals, most of which happen during the second half of the year. As a result, the Group typically reports lower revenues for the first half of the year, than the second half.

#### (b) Segment reporting

The Group manages its businesses by sales channel categories. In a manner consistent with the way in which information is reported internally to the Group's most senior executive management for the purposes of resource allocation and performance assessment, the Group has presented the following five reportable segments. No operating segments have been aggregated to form the following reportable segments.

Direct sales to online customers: this segment engaged in sales of edible bird's nest products to retail customers through online platform.

Direct sales to offline customers: this segment engaged in sales of edible bird's nest products to retail customers in brick-and-mortar stores.

Sales to offline distributors: this segment engaged in sales of edible bird's nest products to offline distributors.

### 3 营业收入及分部报告 (续)

#### (a) 收入 (续)

121(a) 15  
u w

#### 季节性经营

u  
u w u  
w u  
w

#### (b) 分部报告

w  
u  
w  
u w

ë {  
w

ë { w

ë { w



### 3 REVENUE AND SEGMENT REPORTING (Continued)

### 3 营业收入及分部报告 (续)

#### (b) Segment reporting (continued)

#### (b) 分部报告 (续)

Direct sales to E-commerce platforms: this segment engaged in sales of edible bird's nest products to online platforms.

€ {  
W

Sales to online distributors: this segment engaged in sales of edible bird's nest products to online distributors.

€ {  
W

#### (i) Segment results

#### (i) 分部业绩

For the purposes of assessing segment performance and allocating resources between segments, the Group's most senior executive management monitors the results attributable to each reportable segment on the following bases:

u  
{

Revenue and expenses are allocated to the reportable segments with reference to sales generated by those segments and direct expenses incurred by those segments respectively. The measure used for reporting segment result is gross profit which is calculated based on revenue less cost of sales for the relevant segment. No inter-segment sales have occurred during the interim period. Assistance provided by one segment to another, including sharing of assets and technical know-how, is not measured.

W  
W  
W  
—  
-

The Group's other operating income and expenses, such as other net income, selling and distribution expenses, administrative expenses, research and development expenses, impairment loss on goodwill, finance costs and assets and liabilities are not measured under individual segments. Accordingly, neither information on segment assets and liabilities nor information concerning capital expenditure, other operating income and expenses is presented.

— v  
v v v  
v  
- w u  
u  
v  
w



J ¼ 2 •, Ì S • W

(Expressed in Renminbi unless otherwise indicated)

### 3 REVENUE AND SEGMENT REPORTING (Continued)

#### (b) Segment reporting (continued)

##### (i) Segment results (continued)

Information regarding the Group's reportable segments as provided to the Group's most senior executive management for the purposes of resource allocation and assessment of segment performance for the six months ended 2025 and 2024 is set out below.

### 3 x ] q ± Å S € f •

#### (b) ± Å S € f •

##### (i) ± Å 8 6 € f •

u

w

|              | Six months ended 30 June 2025    |                                   |                               |                                      |                              |           |
|--------------|----------------------------------|-----------------------------------|-------------------------------|--------------------------------------|------------------------------|-----------|
|              | Direct sales to online customers | Direct sales to offline customers | Sales to offline distributors | Direct sales to E-commerce platforms | Sales to online distributors | Total     |
|              | ¥ £ ¢ j                          | ¥ £ ¢ h                           | £ ¢ h                         | ¥ £                                  | £ ¢ j                        | <         |
|              | Ò V /                            | Ò V /                             | ¼ V V /                       | e ; ( V /                            | ¼ V V /                      |           |
|              | RMB000                           | RMB000                            | RMB000                        | RMB000                               | RMB000                       | RMB000    |
|              | [ O Æ w ©                        | [ O Æ w ©                         | [ O Æ w ©                     | [ O Æ w ©                            | [ O Æ w ©                    | [ O Æ w © |
| Revenue      | 462,601                          | 157,137                           | 224,781                       | 147,480                              | 22,582                       | 1,014,581 |
| Gross profit | 222,042                          | 107,725                           | 116,616                       | 73,258                               | 7,889                        | 527,530   |

#### Six months ended 30 June 2024

|              | Direct sales to online customers | Direct sales to offline customers | Sales to offline distributors | Direct sales to E-commerce platforms | Sales to online distributors | Total     |
|--------------|----------------------------------|-----------------------------------|-------------------------------|--------------------------------------|------------------------------|-----------|
|              | RMB 000                          | RMB 000                           | RMB 000                       | RMB 000                              | RMB 000                      | RMB 000   |
| Revenue      | 485,207                          | 164,853                           | 253,719                       | 141,477                              | 14,048                       | 1,059,304 |
| Gross profit | 209,953                          | 108,507                           | 123,715                       | 65,951                               | 5,673                        | 513,799   |



### 3 REVENUE AND SEGMENT REPORTING (Continued)

### 3 营业收入及分部报告 (续)

#### (b) Segment reporting (continued)

#### (b) 分部报告 (续)

##### (ii) Reconciliation of reportable segment profit or loss

##### (ii) 可报告分部利润或亏损的调节

|                                       | Six months ended 30 June |           |
|---------------------------------------|--------------------------|-----------|
|                                       | 2025                     | 2024      |
|                                       | Z g Z ž Ě                | RMB000    |
|                                       | [ O Æ w ©                | RMB 000   |
| Total reportable segment gross profit | 527,530                  | 513,799   |
| Other net income                      | 6,319                    | 7,973     |
| Selling and distribution expenses     | (333,484)                | (365,272) |
| Administrative expenses               | (66,582)                 | (62,604)  |
| Research and development expenses     | (11,349)                 | (12,358)  |
| Impairment loss on goodwill           | (9,179)                  |           |
| Finance costs                         | (3,206)                  | (3,532)   |
| Consolidated profit before taxation   | 110,049                  | 78,006    |

##### (iii) Geographic information

##### (iii) 地区信息

The following table sets out information about the geographical location of (i) the Group's revenue from external customers and (ii) the Group's property, plant and equipment, intangible assets and goodwill (specified non-current assets). The geographical location of customers is based on the location at which the goods delivered. The geographical location of the specified non-current assets is based on the physical location of the asset, in the case of property, plant and equipment, and the location of the operation to which they are allocated, in the case of intangible assets and goodwill.

|   | (i) | (ii) |
|---|-----|------|
|   |     | v    |
|   | v   | →    |
|   | 3   |      |
| w |     |      |
|   | w   | v    |
| u |     | z    |
|   | u   |      |
|   | w   |      |



2024年中期报告

(Expressed in Renminbi unless otherwise indicated)

### 3 REVENUE AND SEGMENT REPORTING (Continued)

(b) Segment reporting (continued)

(iii) Geographic information (continued)

Revenues from external customers

|                  | Six months ended 30 June         |           | Specified non-current assets                    |                     |
|------------------|----------------------------------|-----------|---|---------------------|
|                  | 2025                             | 2024      | At 30 June 2025                                 | At 31 December 2024 |
|                  | Z g Z ž Ě<br>RMB000<br>[ O Æ w © | RMB 000   | ö Z g Z ž Ě<br>- Ü g d Ú<br>RMB000<br>[ O Æ w © | RMB 000             |
| Chinese Mainland | 1,014,182                        | 1,059,304 | 341,372   | 361,568             |
| Hong Kong        | 106                              |           |   |                     |
| Other countries  | 293                              |           | 2,900   |                     |
|                  | 1,014,581                        | 1,059,304 | 344,272   | 361,568             |

### 4 OTHER NET INCOME

|   | Six months ended 30 June         |         |
|---|----------------------------------|---------|
|   | 2025                             | 2024    |
|   | Z g Z ž Ě<br>RMB000<br>[ O Æ w © | RMB 000 |
| Net fair value changes on financial assets measured at FVPL | 2,244                            | 908     |
| Interest income   | 1,021                            | 3,327   |
| Government grants (note (i))                                | — (i)                            | 2,486   |
| Net gain on disposal of property, plant and equipment       | 20                               | 254     |
| Foreign exchange gain                                       | 9                                | 1,545   |
| Others  | 799                              | (547)   |
|   | 6,319                            | 7,973   |

(i) Government grants were received or receivable from several local government authorities as a recognition of the Group's contribution towards the local economic development.

(i) u w



J ¼ 2 • , Ì S • W

(Expressed in Renminbi unless otherwise indicated) € ð Ö È \$ Þ Ò Ø . d i ø [ Ö Æ • j •

## 5 PROFIT BEFORE TAXATION

5 ö ü Ã ; —

Profit before taxation is arrived at after charging/(crediting):

|  |                      | Six months ended 30 June<br>Ú Ñ Ü g d Ú ß Ñ H Ü |                 |
|--|----------------------|---|-----------------|
|  |                      | 2025<br>Z g Z ž È<br>RMB000<br>[ Ö Æ w ©        | 2024<br>RMB 000 |
| <i>(a) Finance costs</i>   |                      |   |                 |
|  | <i>(a) Ì 11</i>      |   |                 |
| Interest on lease liabilities  |                      | 3,206   | 3,532           |
|  |                      | Six months ended 30 June<br>Ú Ñ Ü g d Ú ß Ñ H Ü |                 |
|  |                      | 2025<br>Z g Z ž È<br>RMB000<br>[ Ö Æ w ©        | 2024<br>RMB 000 |
| <i>(b) Staff costs</i>   |                      |   |                 |
|  | <i>(b) p ^ Ó I #</i> |   |                 |
| Salaries, wages and other benefits                                   | v                    | 135,598   | 139,695         |
| Contributions to defined contribution retirement plan                |                      | 9,235   | 7,779           |
| Equity-settled share-based payment expenses                          |                      | 3,942   |                 |
|  |                      | 148,775   | 147,474         |
| <i>(c) Other items</i>   |                      |   |                 |
|  | <i>(c) I ü ° f</i>   |   |                 |
| Amortisation of intangible assets                                    |                      | 483   | 234             |
| Depreciation charge <sup>#</sup>                                     | #                    |   |                 |
| owned property, plant and equipment                                  | ë v                  | 13,794  | 10,944          |
| right-of-use assets  | ë                    | 16,665  | 11,496          |
| (Reversal of impairment loss) / impairment loss on trade receivables | —                    | (504)   | 68              |
| Impairment loss on other receivables                                 |                      | 419   | 706             |
| Cost of inventories <sup>#</sup> (note 11(a))                        | # 11(a)              | 436,299   | 492,280         |

<sup>#</sup> Cost of inventories includes RMB53,635,000 (six months ended 30 June 2024: RMB55,525,000) relating to staff costs and depreciation, which amount is also included in the respective total amounts disclosed separately above or note 5(b) for each of these types of expenses.

# 53,635,000 —  
{ 55,525,000 ~ u  
5(b)  
w



## 6 INCOME TAX IN THE CONSOLIDATED STATEMENT OF PROFIT OR LOSS

(a) Taxation in the consolidated statement of profit or loss represents:

|   |         | Six months ended 30 June |          |
|---|---------|--------------------------|----------|
|   |         | 2025                     | 2024     |
|   |         | Z g Z ž Ě                | RMB 000  |
|   |         | [ O Æ w ©                | RMB 000  |
| Current tax                                       | C , ü ° |                          |          |
| PRC Corporate Income Tax ( CIT )                  |         | 40,945                   | 34,883   |
| Under-provision in respect of prior years         |         | 2,429                    | 143      |
| Deferred tax                                      | È · ü ° | 43,374                   | 35,026   |
| Origination and reversal of temporary differences |         | (10,776)                 | (17,065) |
|   |         | 32,598                   | 17,961   |

According to the PRC Corporate Income Tax Law and its implementation regulations, certain subsidiaries of the Group were qualified as Small Low-profit Enterprise and enjoyed a reduced corporate income tax rate of 20% and a 75% deduction of annual assessable profits for the six months ended 30 June 2025 and 2024. All of the other Chinese Mainland subsidiaries of the Group and the Company are subject to CIT at a statutory rate of 25% for the six months ended 30 June 2025 and 2024.

a u «  
2 3 u  
20%  
75% w  
25%  
w

According to the relevant tax rules in Chinese Mainland, qualified research and development expenses are allowed for bonus deduction for income tax purpose, as a result, an additional 100% of the qualified research and development expenses could be deemed as deductible expenses for the six months ended 30 June 2025 and 2024.

u u u  
100% w



## 7 EARNINGS PER SHARE

## 7 每股盈利

### (a) Basic earnings per share

### (a) 基本每股盈利

The calculation of basic earnings per share is based on the profit attributable to ordinary equity shareholders of the Company and the weighted average number of ordinary shares in issue during the interim period.

w

#### (i) Weighted average number of ordinary shares

#### (i) 加权平均普通股数

|  |                        | Six months ended 30 June |         |
|--|------------------------|--------------------------|---------|
|  |                        | 截至 6 月 30 日止六个月的         |         |
|  |                        | 2025                     | 2024    |
|  |                        | Z g Z ž Ě                | 000     |
|  |                        | 000                      | 000     |
|  |                        | w p                      |         |
| Ordinary shares in issue at 1 January                        |                        | 465,500                  | 465,500 |
| Effect of shares held for H Share Incentive Scheme (note 15) | H<br>— 15 <sup>~</sup> | (9,294)                  | (25)    |
| Weighted average number of ordinary shares at 30 June        |                        | 456,206                  | 465,475 |

### (b) Diluted earnings per share

### (b) 稀释每股盈利

For the six months ended 30 June 2025, the effects of unvested shares held for H Share Incentive Scheme were not included in the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. The Company did not have other potential ordinary shares and therefore the amounts of diluted earnings per share were the same as basic earnings per share for the six months ended 30 June 2025.

u H

u

w

u

u

u

w

For the six months ended 30 June 2024, there are no dilutive potential ordinary shares, and therefore, the amounts of diluted earnings per share are the same as basic earnings per share for the period.

u

u

u

w



## NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

2024年6月30日止期间

(Expressed in Renminbi unless otherwise indicated)

### 8 PROPERTY, PLANT AND EQUIPMENT

#### (a) Right-of-use assets

During the six months ended 30 June 2025, the Group entered into a number of lease agreements for use of retail stores and administrative offices, and therefore recognised the additions to right-of-use assets of RMB12,189,000 (six months ended 30 June 2024: RMB21,137,000).

The Group leased a number of retail stores which contain variable lease payment terms that are based on sales generated from the retail stores and minimum annual lease payment terms that are fixed. These payment terms are common in retail stores in Chinese Mainland where the Group operates. The amount of fixed and variable lease payments for the six months ended 30 June 2025 and 2024 is summarised below:

### 8 物业、厂房及设备

#### (a) 使用权资产

|            |   |            |   |
|------------|---|------------|---|
| u          | u | 12,189,000 | — |
|            |   |            | { |
| 21,137,000 | w |            |   |
|            |   |            | u |
| w          |   |            | w |
|            |   |            | { |

|   | Six months ended 30 June 2025 |                   |                |
|---|-------------------------------|-------------------|----------------|
|   | Fixed payments                | Variable payments | Total payments |
|   | x › ù ›                       | ù ›               | ù › < X        |
|   | RMB000                        | RMB000            | RMB000         |
|   | [ O Æ w ©                     | [ O Æ w ©         | [ O Æ w ©      |
| Retail stores                                       | 6,974                         | 757               | 7,731          |
| Manufacturing facilities and administrative offices | 12,215                        |                   | 12,215         |
|   | 19,189                        | 757               | 19,946         |



2025年中期报告  
 (Expressed in Renminbi unless otherwise indicated)

## 8 PROPERTY, PLANT AND EQUIPMENT (Continued)

### (a) Right-of-use assets (continued)

## 8 使用权资产 (续)

### (a) 使用权资产 (续)

Six months ended 30 June 2024

|   | Fixed payments | Variable payments | Total payments |
|---|----------------|-------------------|----------------|
|   | RMB 000        | RMB 000           | RMB 000        |
| Retail stores                                       | 5,263          | 2                 | 5,265          |
| Manufacturing facilities and administrative offices | 13,614         |                   | 13,614         |
|   | 18,877         | 2                 | 18,879         |

### (b) Acquisitions and disposals of owned assets

During the six months ended 30 June 2025, the Group acquired items of property, plant and equipment which mainly include leasehold improvement, machinery and office and other equipment with a cost of RMB8,762,000 (six months ended 30 June 2024: RMB100,663,000). Items of property, plant and equipment with a net book value of RMB7,000 were disposed during the six months ended 30 June 2025 (six months ended 30 June 2024: RMB27,000), resulting in a gain on disposal of RMB1,000 (six months ended 30 June 2024: loss on disposal of RMB10,000).

### (b) 自有资产的购置和处置

|           |        |             |
|-----------|--------|-------------|
| —         | —      | —           |
| 8,762,000 | —      | 100,663,000 |
| —         | —      | 7,000       |
| —         | —      | 27,000      |
| —         | —      | 1,000       |
|           | 10,000 | —           |



# NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

2024年半年度报告

(Expressed in Renminbi unless otherwise indicated)

## 9 GOODWILL

RMB 000

|  |  |         |
|--|--|---------|
| Cost:  |  |         |
| At 1 January 2024                                      |  | 75,165  |
| Addition through business combination                  |  | 2,000   |
|  |  | <hr/>   |
| At 31 December 2024 and 30 June 2025                   |  | 77,165  |
| Accumulated impairment losses:                         |  |         |
| At 1 January 2024, 31 December 2024 and 1 January 2025 |  |         |
| Impairment loss recognised                             |  | (9,179) |
|  |  | <hr/>   |
| At 30 June 2025  |  | (9,179) |
| Carrying amount:                                       |  |         |
| At 30 June 2025  |  | 67,986  |
|  |  | <hr/>   |
| At 31 December 2024                                    |  | 77,165  |
|  |  | <hr/>   |



## 9 GOODWILL(continued)

Goodwill is allocated to the Group's cash-generating units (CGUs) identified according to city of operation and operating segment as follows:

|   |   |     | At<br>30 June<br>2025 | At<br>31 December<br>2024 |
|---|---|-----|-----------------------|---------------------------|
|   |   |     | 人民币<br>千元             | 人民币<br>千元                 |
|   |   |     | RMB000                | RMB000                    |
|   |   |     | [OAE w ©]             |                           |
| Beijing Tianfeiyuan Trading Co., Ltd. ( Beijing<br>Tianfeiyuan ) offline retail | — | 3-è | 22,430                | 31,609                    |
| Harbin Jinyanhui Trading Co., Ltd. ( Harbin<br>Jinyanhui ) offline retail       | — | 3-è | 17,301                | 17,301                    |
| Changchun Jinyanhui Trading Co., Ltd.<br>( Changchun Jinyanhui ) offline retail | — | 3-è | 15,245                | 15,245                    |
| Taiyuan Jixiangyan Trading Co., Ltd. ( Taiyuan<br>Jixiangyan ) offline retail   | — | 3-è | 11,010                | 11,010                    |
| Nanning Jinyanli Trading Co., Ltd. ( Nanning<br>Jinyanli ) offline retail       | — | 3-è | 2,000                 | 2,000                     |
|   |   |     | 67,986                | 77,165                    |



## NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

2025

(Expressed in Renminbi unless otherwise indicated)

u

### 9 GOODWILL(continued)

#### Beijing Tianfeiyuan offline retail

The recoverable amount of the CGU Beijing Tianfeiyuan is determined based on value-in-use calculations. The Group engaged an independent professional valuer to assist with the calculation. These calculations use cash flow projections based on financial budgets approved by management covering a five-year period. The key assumptions used in estimating the recoverable amount are as follows:

|  |                |                |
|--|----------------|----------------|
| Annual growth rate of revenue during five-year forecast period     | 0% - 2%        | 0% - 2%        |
| Estimated weighted average growth rate beyond the five-year period | 2%             | 2%             |
| Pre-tax discount rate  | 9.69% - 12.07% | 9.69% - 12.07% |

The financial performance of Beijing Tianfeiyuan has been lower than expectation in the first half of 2025. As a result, the impairment loss of RMB9,179,000 related to the CGU Beijing Tianfeiyuan was recognised during the six months ended 30 June 2025 as it has been reduced to its recoverable amount as at 30 June 2025. Any adverse change in the assumptions used in the calculation of recoverable amount would result in further impairment losses.

### 9 ' € f •

/Ä - ò Ñ Þ hg/

ë  
w  
w

w  
{

w u ë  
9,179,000

u  
w

w



30

(Expressed in Renminbi unless otherwise indicated) 人民币报表 (除另有说明外)

## 10 EQUITY SECURITIES DESIGNATED AT FVOCI

10 8 > % 2 @<sup>a</sup> = ] l ü Ö E  
& x B Y p I Ç N

|  | At<br>30 June<br>2025<br>Z g Z ž Ě<br>Ü g d Ú<br>RMB000<br>[ O Æ w © | At<br>31 December<br>2024<br>RMB 000 |
|--|--|--------------------------------------|
| Investments in listed equity securities PT.<br>ESTA INDONESIA ( PT. ESTA ) | PT. ESTA INDONESIA<br>PT. ESTA <sup>3</sup>                          |                                      |
|  | 27,874   | 35,948                               |

PT. ESTA is incorporated in Republic of Indonesia and listed on Indonesia Stock Exchange, and engaged in edible bird's nests trading and industrial business. The Group held 5.00% of equity interest in PT. ESTA as at 30 June 2025 (31 December 2024: 4.8%). The Group designated its investment in PT. ESTA at FVOCI (non-recycling), as the investment is held for strategic purposes. No dividends were received on this investment during the six months ended 30 June 2025.

PT. ESTA

u  
w u  
PT. ESTA 5.00%  
{ 4.8% w  
u PT. ESTA  
—  
w  
u w

## 11 INVENTORIES

11 Ä -

|                                   | At<br>30 June<br>2025<br>Z g Z ž Ě<br>Ü g d Ú<br>RMB000<br>[ O Æ w © | At<br>31 December<br>2024<br>RMB 000 |
|-----------------------------------|--|--------------------------------------|
| Raw materials                     | 125,717  | 197,742                              |
| Work in progress                  | 21,251   | 40,561                               |
| Finished goods                    | 31,844   | 79,096                               |
| Goods in transit                  | 7,059  | 20,639                               |
| Packaging                         | 12,191   | 15,540                               |
| Right to recover returned goods   | 137  | 237                                  |
|                                   | 198,199  | 353,815                              |
| Less: Write-down of inventories { | (601)  | (617)                                |
|                                   | 197,598  | 353,198                              |



30V

(Expressed in Renminbi unless otherwise indicated)

## 11 INVENTORIES(continued)

11 存货(续)

(a) The analysis of the amount of inventories recognised as an expense and included in profit or loss is as follows:

(a) 计入当期损益的存货成本及其对应的存货跌价准备的分析如下:

|  | Six months ended 30 June |         |
|--|--------------------------|---------|
|  | 2025                     | 2024    |
|  | Z g Z ž Ě                | RMB 000 |
|  | [ O Æ w ©                | RMB 000 |
| Carrying amount of inventories sold  | 435,309                  | 489,451 |
| Carrying amount of inventories recognised as research and development expenses | 265                      | 1,599   |
| Write-down of inventories  | 725                      | 1,230   |
|  | 436,299                  | 492,280 |

## 12 TRADE RECEIVABLES, OTHER RECEIVABLES AND PREPAYMENTS

12 应收账款、其他应收款及预付款项

(a) Trade and other receivables

(a) 应收账款和其他应收款

|   | At           |                  |
|---|--------------|------------------|
|   | 30 June 2025 | 31 December 2024 |
|   | õ Z g Z ž Ě  | RMB 000          |
|   | - Û g d Ú    | RMB 000          |
|   | [ O Æ w ©    | RMB 000          |
| Trade receivables, net of loss allowance      | —            | -                |
| third parties                                 | ë 68,268     | 92,367           |
| Deposits                                      | 5,035        | 4,102            |
| Amounts due from related parties (note 19(c)) | —            | 19(c) 1,900      |
| VAT recoverable                               | 18,696       | 36,496           |
| Government grants receivables                 |              | 27,026           |
| Other receivables                             | 1,999        | 1,765            |
|   | 95,898       | 163,656          |



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

J ¼ 2 Ì S W

(Expressed in Renminbi unless otherwise indicated) \$ P Ô 8 . d i ø [ O Æ • j •

12 TRADE RECEIVABLES, OTHER RECEIVABLES AND PREPAYMENTS (continued) 12 q ø Ð x › ° e l ü Ð x › ° ç k ù › ° € f •

(a) Trade and other receivables (continued) (a) q ø ç l ü Ð x › ° € f •

As at 30 June 2025 and 31 December 2024, all of the trade and other receivables are expected to be recovered or recognised as expense within one year.

w

Ageing analysis

\* g ±

As of the end of the reporting period, the ageing analysis of trade receivable (which are included in trade and other receivables), based on the invoice date and net of loss allowance, is as follows:

u —

-

{

|                        |   | At<br>30 June<br>2025<br>ö Z g Z ž Ě<br>- Ü g d Ú<br>RMB000<br>[ O Æ w © | At<br>31 December<br>2024<br>RMB 000 |
|------------------------|---|--|--------------------------------------|
| Current (not past due) | — | 68,232   | 92,070                               |
| Over 3 months past due |   | 36   | 297                                  |
|                        |   | 68,268   | 92,367                               |

Trade debtors are due within 30 to 90 days from the date of billing. Debtors with balances that are more than 3 months past due are requested to settle all outstanding balances before any further credit is granted.

w

30 90

3

u

u

w



30

(Expressed in Renminbi unless otherwise indicated)

## 12 TRADE RECEIVABLES, OTHER RECEIVABLES AND PREPAYMENTS (continued)

## 12 交易應收賬項、其他應收賬項及預付款項 (續)

### (b) Prepayments

### (b) 預付款項

|                           |   | At<br>30 June<br>2025 | At<br>31 December<br>2024 |
|---------------------------|---|-----------------------|---------------------------|
|                           |   | 人民幣<br>千元             | 人民幣<br>千元                 |
| Prepayments for:          | { |                       |                           |
| advertising expenses      | € | 53,370                | 58,076                    |
| purchase of raw materials | € | 3,737                 | 2,455                     |
| others                    | € | 18,606                | 15,465                    |
|                           |   | 75,713                | 75,996                    |

## 13 CASH AND CASH EQUIVALENTS

## 13 現金及現金等價物

|  |         | At<br>30 June<br>2025 | At<br>31 December<br>2024 |
|--|---------|-----------------------|---------------------------|
|  |         | 人民幣<br>千元             | 人民幣<br>千元                 |
| Cash at bank and on hand (note (i))              | — (i)⁻  | 503,424               | 410,724                   |
| Cash balances with payment platforms (note (ii)) | — (ii)⁻ | 14,870                | 9,784                     |
| Cash and cash equivalents                        |         | 518,294               | 420,508                   |

(i) As at 30 June 2025, HK\$3,107,000 (equivalent to approximately RMB2,833,000) (31 December 2024: HK\$1,205,000, equivalent to approximately RMB1,116,000) and RMB329,000 (31 December 2024: RMB984,000) were placed with a bank in designated accounts in relation to Share Scheme Trust under the H Share Incentive Scheme as disclosed in note 15.

(i) — u 3,107,000  
— 2,833,000 —  
{ 1,205,000 u  
1,116,000 — 329,000 —  
{ 984,000  
u 15  
H w

(ii) The amount represents cash balances kept with third party payment platforms, which can be withdrawn on demand.

(ii) u w



## NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

截至2025年6月30日止六个月的

(Expressed in Renminbi unless otherwise indicated)

### 13 CASH AND CASH EQUIVALENTS (continued)

As at 30 June 2025, cash and cash equivalents situated in Chinese Mainland amounted to RMB473,727,000 (31 December 2024: RMB375,257,000). Remittance of funds out of Chinese Mainland is subject to relevant rules and regulations of foreign exchange control.

|  |              |               |
|--|--------------|---------------|
|  | 截至2025年6月30日 | 截至2024年12月31日 |
|  | 473,727,000  | 375,257,000   |

### 14 TRADE AND OTHER PAYABLES

截至2025年6月30日

|  | At 30 June 2025 | At 31 December 2024 |
|--|-----------------|---------------------|
| Trade payables                                   | 34,897          | 66,895              |
| Receipts in advance                              | 46,567          | 47,404              |
| Salary and welfare payables                      | 34,142          | 51,579              |
| Other payables and accruals                      | 36,055          | 42,086              |
| Financial liabilities measured at amortised cost | 151,661         | 207,964             |
| Other tax payables                               | 21,863          | 9,061               |
| Refund liabilities:                              |                 |                     |
| arising from right of return                     | 226             | 428                 |
| arising from sales rebates                       | 25,573          | 53,597              |
|  | 199,323         | 271,050             |

All trade and other payables are expected to be settled or recognised as income within one year or are repayable on demand.



30

(Expressed in Renminbi unless otherwise indicated)

## 14 TRADE AND OTHER PAYABLES (continued)

As of the end of the reporting period, the ageing analysis of trade payables (which are included in trade and other payables), based on the invoice date, is as follows:

|                                   | At<br>30 June<br>2025 | At<br>31 December<br>2024 |
|-----------------------------------|-----------------------|---------------------------|
|                                   | RMB000                | RMB000                    |
| Within 3 months                   | 31,557                | 65,191                    |
| Over 3 months but within 6 months | 1,703                 | 790                       |
| Over 6 months but within 9 months | 1,349                 | 914                       |
| Over 9 months but within 1 year   | 288                   |                           |
|                                   | <b>34,897</b>         | <b>66,895</b>             |

## 15 EQUITY SETTLED SHARE BASED TRANSACTIONS

### H Share Incentive Scheme

On 25 March 2024, the H share employee incentive scheme (the H Share Incentive Scheme) was approved by the extraordinary general meeting of the Company. The purpose of H Share Incentive Scheme is mainly to provide incentives and rewards to eligible participants for their contribution or potential contribution to continue leading the future success of the Group.

Following the implementation of the H Share Incentive Scheme, the Company has appointed a third-party trustee (Trustee) to constitute a trust plan under the trust management agreement (Share Scheme Trust) for repurchasing, holding, and administering the Company's shares under H Share Incentive Scheme. The directors of the Company consider that it is appropriate to consolidate Share Scheme Trust as the Company has power to govern the relevant activities of Share Scheme Trust and can derive benefits from the contributions of the eligible participants who are awarded with the shares under the H Share Incentive Scheme.



# NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

J 3/4 2 Ì S W

(Expressed in Renminbi unless otherwise indicated) \$ P Ô 8 . d i ø [ O Æ • j •

## 15 EQUITY SETTLED SHARE BASED TRANSACTIONS (continued)

15 ø Æ B Q Y p ... ù > t ø  
€ f •  
H p ç , Æ € f •

### H Share Incentive Scheme (continued)

Eligible participants as approved by the Company would be granted the trust units ( Trust Units ) which give the eligible participants the right to pay the subscription price when the Trust Units are vested. After the Trust Units are duly vested, the Trustee shall allocate and dispose the corresponding H shares of the Company underlying the H Share Incentive Scheme ( Restricted H Shares ) in accordance with the instruction of the eligible participants. The eligible participants shall not have any rights (such as voting rights, allotment rights or right issues, etc.) attached to any of the Restricted H Shares except for dividend rights. The directors of the Company consider the H Share Incentive Scheme provides a longer-term option to subscribe Trust Units at a specified subscription price and is, in substance, a share option scheme. Accordingly, the trust units granted are accounted for as share options.

|     |   |         |       |
|-----|---|---------|-------|
|     | → |         | 3 ~ u |
|     |   | u       |       |
|     |   | w       |       |
|     | u |         |       |
|     |   | H       |       |
| H → |   | H 3 ~ w | u     |
|     |   |         | H     |
| —   |   | v       | ~ w   |
|     |   | u H     |       |
| u   |   |         | w u   |
|     |   |         | w     |



30

(Expressed in Renminbi unless otherwise indicated)

## 15 EQUITY SETTLED SHARE BASED TRANSACTIONS (continued)

15 0 Æ B Q Y p ... ù > t ø  
€ f •  
H p ç , 0 € f •

### H Share Incentive Scheme (continued)

Subject to meeting the service and appraised conditions in respect of the Company's revenue and profits in the financial year prior to a given vesting date, the Trust Units will be vested in the following manner:

|              | Vesting dates<br>à n Ú , | Proportion of vesting<br>à n â 7 |
|--------------|--------------------------|----------------------------------|
| First batch  | July 2026                | 40.00%                           |
| Second batch | July 2027                | 30.00%                           |
| Third batch  | July 2028                | 30.00%                           |

Movements in the number of Trust Units granted to directors and employees are as follows:

|   | 2025<br>Z g Z ž Ě                                  |  | 2024                     |   |
|---|--|--|--------------------------|---|
|   | Number of<br>Trust Units<br>! Ä a B Æ<br>... X p f | Equivalent of<br>number of<br>Restricted<br>H Shares<br>' ... õ a " S<br>H p p f | Number of<br>Trust Units | Equivalent of<br>number of<br>Restricted<br>H Shares<br>H |
| As at 1 January                             | 66,984,618   | 6,284,500  |                          |   |
| Granted during the<br>period                | 9,752,712  | 915,000  |                          |   |
| Granted but not yet<br>vested as at 30 June | 76,737,330   | 7,199,500  |                          |   |





30

(Expressed in Renminbi unless otherwise indicated)

## 15 EQUITY SETTLED SHARE BASED TRANSACTIONS (continued)

15 0 Æ B Q Y p ... ù > t ø  
€ f •

### H Share Incentive Scheme (continued)

H p ç , 0 € f •

Fair value of share options and assumption

|                        | The first batch<br>Trust Units<br>K S - ! Ä<br>a B Æ ... X | The second batch<br>Trust Units<br>K Z - ! Ä<br>a B Æ ... X | The third batch<br>Trust Units<br>K g - ! Ä<br>a B Æ ... X |
|------------------------|--|---|--|
| Share price            | HK\$6.30<br>6.30   | HK\$6.30<br>6.30  | HK\$6.30<br>6.30   |
| Exercise price         | HK\$4.85<br>4.85   | HK\$4.85<br>4.85  | HK\$4.85<br>4.85   |
| Time to maturity       | 1 year<br>1  | 2 year<br>2   | 3 year<br>3  |
| Exercise multiple      | 2.2-2.8  | 2.2-2.8   | 2.2-2.8  |
| Volatility             | 30.14%-31.68%  | 30.14%-31.68%   | 30.14%-31.68%  |
| Risk free rate         | 2.79%-2.87%  | 2.79%-2.87%   | 2.79%-2.87%  |
| Post-vesting exit rate | 0%-8.07%   | 0%-8.07%  | 0%-8.07%   |

The volatility is based on the historic volatility (calculated based on the weighted average remaining life of the share options), adjusted for any expected changes to future volatility based on publicly available information. Changes in the subjective input assumptions could materially affect the fair value estimate.

—  
u

w

w



(Expressed in Renminbi unless otherwise indicated)

## 16 CAPITAL, RESERVES AND DIVIDENDS

### (a) Dividends

- (i) Dividends payable to equity shareholders of the Company attributable to the interim period

The directors of the Company did not recommend the payment of an interim dividend for the six months ended 30 June 2025 and 2024.

- (ii) Dividends payable to equity shareholders of the Company attributable to the previous financial year, approved and paid during the interim period

## 16 資本、儲備及股息

### (a) 股息

- (i) 應付予本公司權益股東之股息

萬

- (ii) 應付予本公司權益股東之股息

|   |            | Six months ended 30 June |         |
|---|------------|--------------------------|---------|
|   |            | 2025                     | 2024    |
|   |            | Z g Z ž Ě                | RMB 000 |
|   |            | [ O Æ w ©                | RMB 000 |
| Final dividend in respect of the previous financial year, approved during the following interim period, of RMB21.5 cents per ordinary share (six months ended 30 June 2024: RMB21.5 cents per ordinary share) | 21.5 —     | 100,083                  | 100,077 |
| Less: dividend for ungranted shares under H Share Incentive Scheme  | { H 21.5 - | (451)                    |         |
|   |            | 99,632                   | 100,077 |
| Less: dividend for unvested shares under H Share Incentive Scheme   | { H        | (1,548)                  |         |
| Unpaid withholding tax  |            | (6,273)                  |         |
| Final dividend in respect of the previous financial year paid   |            | 91,811                   | 100,077 |



# NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

J ¼ 2 • , Ì S • W

(Expressed in Renminbi unless otherwise indicated) 人民币表示，除非另有说明。

## 16 CAPITAL, RESERVES AND DIVIDENDS (continued)

## 16 股本、储备及股息 (续)

### (b) Nature and purpose of reserves

### (b) 储备的性质及用途

#### (i) Share premium

#### (i) 股份溢价

The share premium represents the difference between the par value of the shares of the Company and consideration for the shares issued.

w

#### (ii) Shares held for employee incentive scheme

#### (ii) 为股权激励计划持有的股份

The shares held for employee incentive scheme comprises the cost of the Company's shares held by the Group. At 30 June 2025, the Group held 9,294,400 of the Company's shares (31 December 2024: 9,294,400) included 7,199,500 (31 December 2024: 6,284,500) shares granted pursuant to the H Share Incentive Scheme (see note 15).

w

u

9,294,400

—

{ 9,294,400

u

H

7,199,500

—

{ 6,284,500

—

15 w

#### (iii) Statutory reserve

#### (iii) 法定储备

Pursuant to the Articles of Association of the Group's Chinese Mainland companies and relevant statutory regulations, appropriations to the statutory reserve fund were made at 10% of profit after tax determined in accordance with accounting rules and regulations of Chinese Mainland until the reserve balance reaches 50% of the registered capital. This reserve fund can be utilised in setting off accumulated losses or increasing capital of the Chinese Mainland companies provided that the balance after such conversion is not less than 25% of their registered capital, and is non-distributable other than in liquidation.

u

10%

u

50%

w

u

25%

w

#### (iv) Fair value reserve (non-recycling)

#### (iv) 公允价值储备 (非循环)

The fair value reserve (non-recycling) comprises the cumulative net change in the fair value of equity investments designated at FVOCI under IFRS 9 that are held at the end of the reporting period.

—

9

w



(Expressed in Renminbi unless otherwise indicated)

## 16 CAPITAL, RESERVES AND DIVIDENDS (continued)

### (b) Nature and purpose of reserves (continued)

#### (v) Exchange reserve

The exchange reserve comprises all foreign exchange differences arising from the translation of the financial statements of foreign operations.

#### (vi) Share-based payment reserve

The share-based payment reserve comprises the grant date fair value of unexercised share options granted to employees of the Group that has been recognised in accordance with the accounting policy adopted for share-based payments.

### (c) Capital management

The Group's primary objectives when managing capital are to safeguard the Group's ability to continue as a going concern, so that it can continue to provide returns for shareholders and benefits for other stakeholders, by pricing products and services commensurately with the level of risk and by securing access to finance at a reasonable cost.

The Group actively and regularly reviews and manages its capital structure to maintain a balance between the higher shareholder returns that might be possible with higher levels of borrowings and the advantages and security afforded by a sound capital position, and makes adjustments to the capital structure in light of changes in economic conditions.

The Group monitors its capital structure on the basis of an adjusted net debt-to-capital ratio. For this purpose, adjusted net debt is defined as lease liabilities and adjusted capital comprises all components of equity. In order to maintain or adjust the ratio, the Group may adjust the amount of dividends paid to shareholders, issue new shares, return capital to shareholders, raise new debt financing or sell assets to reduce debt.

16 1e® - ¿ p¹ € f •

(b) ® - Yì / ¿ f Y € f •

(v) . Ò • ê

w

(vi) p ... Ò ù ® -

u

w

(c) I M #

u

u

u

w

u

—

u

w

w

u

u

w

u

v

v

v

w





326

(Expressed in Renminbi unless otherwise indicated) 人民币列示，除非另有说明

## 17 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS

### (a) Financial assets and liabilities measured at fair value

#### Fair value hierarchy

The following table presents the fair value of the Group's financial instruments measured at the end of the reporting period on a recurring basis, categorised into the three-level fair value hierarchy as defined in IFRS 13, *Fair value measurement*. The level into which a fair value measurement is classified is determined with reference to the observability and significance of the inputs used in the valuation technique as follows:

Level 1 valuations: Fair value measured using only Level 1 inputs i.e. unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date

Level 2 valuations: Fair value measured using Level 2 inputs i.e. observable inputs which fail to meet Level 1, and not using significant unobservable inputs. Unobservable inputs are inputs for which market data are not available

Level 3 valuations: Fair value measured using significant unobservable inputs

17 - D ^ H Y ® ^ a = Ž

(a) 2 ® ^ a = Ž Y - D \* ĺ  
À

® ^ a = 4 t

{  
13 u  
w  
u

{  
—

{  
—  
u

w

{





(Expressed in Renminbi unless otherwise indicated)

## 17 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS (continued)

### (a) Financial assets and liabilities measured at fair value (continued)

#### Fair value hierarchy (continued)

During the six months ended 30 June 2025 and 2024, there were no transfers between Level 1 and Level 2, or transfers into or out of Level 3. The Group's policy is to recognise transfers between levels of fair value hierarchy as at the end of the reporting period in which they occur.

#### Valuation techniques and inputs used in Level 2 fair value measurements

The fair value of trust industry protection fund in Level 2 is determined by discounting the estimated future cash flows at risky rate, which is the benchmark interest rate plus the risk premium as at the end of the reporting period.

### (b) Fair value of financial assets and liabilities carried at other than fair value

The carrying amounts of the Group's financial instruments carried at amortised cost were not materially different from their fair values as at 31 December 2024 and 30 June 2025.

17 - D ^ H Y ® ^ a = Ž € f •

(a) 2 ® ^ a = Ž Y - D \* ž

® ^ a = 4 t € f •

u  
u w  
w

—  
-  
w

(b) ( ç 2 ® ^ a = • \* Y - D \* ž  
ž Ä Y ® ^ a =

w





30

(Expressed in Renminbi unless otherwise indicated) 人民币表示，除非另有说明。

## 19 MATERIAL RELATED PARTY TRANSACTIONS (continued)

19 关联方交易 (续)

### (a) Key management personnel remuneration

(a) 关键管理人员薪酬

|   |   | Six months ended 30 June |         |
|---|---|--------------------------|---------|
|   |   | 2025                     | 2024    |
|   |   | Z g Z ž Ě                | RMB 000 |
|   |   | [ O Æ w ©                | RMB 000 |
| Salaries, wages and other benefits                    | v | 6,151                    | 6,286   |
| Contributions to defined contribution retirement plan |   | 215                      | 188     |
| Equity-settled share-based payment expenses           |   | 1,689                    |         |
|   |   | 8,055                    | 6,474   |

Total remuneration is included in staff costs (see note 5(b)).

2 3 —  
5(b) w

### (b) Other transactions with related parties

(b) 关联方其他交易

|  |           | Six months ended 30 June |         |
|--|-----------|--------------------------|---------|
|  |           | 2025                     | 2024    |
|  |           | Z g Z ž Ě                | RMB 000 |
|  |           | [ O Æ w ©                | RMB 000 |
| Trade in nature:                               | q ø ì / j |                          |         |
| Advertising services received                  |           |                          |         |
| Entities controlled by a director of the Group | ë         |                          |         |



05 & 4 50 5) & 6 / " 6 % \* 5 & % \* / 5 & 3 \* . ' \* / " / \$ \* " - 3 & 1 0 3 5  
 J 3/4 2 • , Ì S • W

(Expressed in Renminbi unless otherwise indicated) 00 \$ P08 . d i l [ 0 ~ j

## 19 MATERIAL RELATED PARTY TRANSACTIONS (continued)

19 } ë L ù t ø € f •

### (c) Balances with related parties

(c) ~ ë L ù Y q

|  |           | At<br>30 June<br>2025 | At<br>31 December<br>2024 |
|--|-----------|-----------------------|---------------------------|
|  |           | RMB000                | RMB 000                   |
|  |           | [ O Æ w ©             |                           |
| Trade in nature:   | q ø ì / j |                       |                           |
| Prepayments  |           |                       |                           |
| Entities controlled by a director of the Group                         | ë         | 5,977                 | 4,458                     |
| Other receivables included in trade and other receivables              |           |                       |                           |
| Entities controlled by a director of the Group                         | ë         | 1,900                 | 1,900                     |
| Receipts in advance included in trade and other payables               |           |                       |                           |
| Entity significantly influenced by one of the Controlling Shareholders | ë         | 1,461                 |                           |
| Other payables included in trade and other payables                    |           |                       |                           |
| Entity significantly influenced by one of the Controlling Shareholders | ë         | 927                   | 3,471                     |
| Contract liabilities   |           |                       |                           |
| Entity significantly influenced by one of the Controlling Shareholders | ë         | 3,102                 | 4,198                     |

## 20 NON ADJUSTING EVENTS AFTER THE REPORTING PERIOD

20 S , Y ç Æ + •

On 29 July 2025, 501,200 H shares were repurchased on the Stock Exchange by the Company at a total consideration of approximately HK\$4,262,000.

u  
 501,200 H u  
 4,262,000 w



# DEFINITION

## Ø

|   |  |
|---|--|
| Articles of Association or Articles<br>2 3 2 3  | the articles of association of the Company, as amended from time to time<br>— —  |
| Audit Committee<br>2 3  | the audit committee of the Board   |
| Award Letter<br>2 3   | a letter issued by the Company to each grantee in such form as the Board and/or the Delegatee may from time to time determine, specifying the name of the grantee, the number of Trust Units granted, the vesting criteria and conditions, the vesting date and such other terms and conditions to be determined by the Board and/or the Delegatee that are not inconsistent with the H Share Incentive Scheme<br>u<br>v v v<br>H  |
| Board of Directors or Board<br>2 3  | the board of directors of our Company  |
| CG Code<br>2 3  | the Corporate Governance Code as set out in Appendix C1 to the Listing Rules<br>C1   |
| China, Mainland China or PRC<br>2 3v2 3 2<br>3  | People's Republic of China, excluding, for the purposes of this interim report and for geographical reference only and except where the context requires otherwise, Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan<br>u u v<br>u   |
| Company, our Company, Group,<br>our Group, we, us or Yan Palace<br>2 3v2 3v2 3v2<br>3v2 3 2 3 | Xiamen Yan Palace Bird's Nest Industry Co., Ltd. ( )<br>(formerly known as Xiamen Yan Palace Bioengineering Co., Ltd. ( )<br>) , a joint stock company established in the PRC with limited liability on December 23, 2020, or, where the context requires (as the case may be), its predecessor, Xiamen Yan Palace Biological Engineering Development Co., Ltd. ( )<br>) , a company established in the PRC with limited liability on October 31, 2014<br>— — u —<br>— u — |



Q E

|  |   |
|--|---|
| <p>Controlling Shareholders</p> <p>2 3</p>                     | <p>has the meaning ascribed thereto under the Listing Rules and unless the context requires otherwise, refers to Mr. Huang, Mr. Zheng, Mr. Li, Ms. Xue, Xiamen Suntama and Jinyan Tengfei LP</p> <p style="text-align: center;">u u v v v</p> <p style="text-align: center;">v</p>  |
| <p>CSRC</p> <p>2 3</p>   | <p>the China Securities Regulatory Commission ( )</p>   |
| <p>Delegatee(s)</p> <p>2 3</p>                                 | <p>the Board committee(s) and/or person(s) delegated by the Board</p>   |
| <p>Director(s)</p> <p>2 3</p>                                  | <p>the director(s) of our Company</p>   |
| <p>EBN+ products</p> <p>2 + 3</p>                              | <p>ready-to-serve EBN products (with an EBN feed rate of 1% or above and up to 5%) enhanced with other ingredients and/or nutrients, such as ginseng and gamma-aminobutyric acid</p> <p style="text-align: center;">— — — — —</p> <p style="text-align: center;">— 1% 5% — — — — —</p>  |
| <p>edible bird s nests or EBN</p> <p>2 3 2 EBN<sup>3</sup></p> | <p>nests created by swiftlets with their saliva. EBN is highly valued in Chinese culture and has been a renowned delicacy in Chinese cuisine for over 400 years. It is known for its nutritional profile, which includes, among others, sialic acid, amino acid, collagen, glycoprotein, antioxidants, calcium, potassium, iron, magnesium and hormones. Traditional Chinese medicine attributes various health benefits to EBN, such as promoting overall wellness, boosting the immune system, enhancing focus and concentration, increasing energy and metabolism and regulating circulation. Modern scientific studies conducted by authoritative sources have further validated the perceived health benefits of EBN products</p> <p style="text-align: center;">w u u 400</p> <p style="text-align: center;">v v v v w v v v v</p> <p style="text-align: center;">v v v v w u</p> <p style="text-align: center;">v v v v v v v</p> <p style="text-align: center;">w</p> |



DEFINITION  
Q Ě



|                           |  |
|---------------------------|--|
| Hong Kong                 | the Hong Kong Special Administrative Region of the PRC   |
| 2 3                       |  |
| Hongyan Investment LP     | Beijing Hongyan Equity Investment Center (Limited Partnership) ( ), a limited partnership established in the PRC on October 20, 2014   |
| 2 3                       | — u  |
| IFRS Accounting Standards | includes all applicable individual IFRS Accounting Standards, IAS Standards and IFRIC Interpretations issued by the International Accounting Standards Board (IASB)  |
| 2 3                       | — 2 3 v  |
| Jinjun Hongyan LP         | Pingtian Jinjun Hongyan Investment Partnership LP ( ), a limited partnership established in the PRC on April 20, 2018  |
| 2 3                       | — u  |
| Jinyan Tengfei LP         | Xiamen Jinyan Tengfei Equity Investment Partnership (Limited Partnership) ( ), a limited partnership established in the PRC on December 14, 2020 and an employee incentive platform of our Group and one of our Controlling Shareholders |
| 2 3                       | — u u  |
| Listing                   | the listing of the H Shares on the Main Board of the Stock Exchange  |
| 2 3                       | H  |
| Listing Date              | December 12, 2023, being the date on which the H Shares were listed on the Main Board of the Stock Exchange  |
| 2 3                       | u H  |
| Listing Rules             | the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time   |
| 2 3                       | — -  |



|                                      |   |
|--------------------------------------|---|
| Model Code                           | the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules       |
| 2 3                                  | C3  |
| Mr. Huang                            | Mr. HUANG Jian ( ), our chairman of the Board of Directors, executive Director and one of our Controlling Shareholders        |
| 2 3                                  | u v   |
| Mr. Li                               | Mr. LI Youquan ( ), our general manager, executive Director and one of our Controlling Shareholders                           |
| 2 3                                  | u v   |
| Mr. Zheng                            | Mr. ZHENG Wenbin ( ), our vice chairman of the Board of Directors, executive Director and one of our Controlling Shareholders |
| 2 3                                  | u v   |
| Ms. Xue                              | Ms. XUE Fengying ( ), one of our Controlling Shareholders and the spouse of Mr. Zheng   |
| 2 3                                  | u   |
| Nomination Committee                 | the nomination committee of the Board   |
| 2 3                                  |   |
| Prospectus                           | the prospectus of the Company dated November 30, 2023   |
| 2 3                                  |   |
| Remuneration and Appraisal Committee | the remuneration and appraisal committee of the Board   |
| 2 3                                  |   |
| Renminbi or RMB                      | Renminbi, the lawful currency of the PRC  |
| 2 3                                  |   |
| Reporting Period                     | six months from January 1, 2025 to June 30, 2025  |
| 2 3                                  |   |





|                     |   |
|---------------------|---|
| Trustee             | the trustee to be appointed by the Company for the purpose of the trust constituted under the trust management agreement to be entered into pursuant to the H Share Incentive Scheme                                      |
| 2 3                 | H   |
| Trust Unit(s)       | unit(s) of beneficial rights under the Trust as granted to the grantees by the Board and/or the Delegatee(s) and as divided by the trustee to be appointed by the Company for the purpose of the H Share Incentive Scheme |
| 2 3                 | H   |
| United States       | the United States of America, its territories, its possessions and all areas subject to its jurisdiction  |
| 2 3                 | u v   |
| USD or US\$         | US dollars, the lawful currency of the United States  |
| 2 3                 |   |
| Xiamen Jinyanlai LP | Xiamen Jinyanlai Investment Partnership (Limited Partnership) ( ( )), a limited partnership established in the PRC on July 17, 2015   |
| 2 3                 | — u   |
| Xiamen Suntama      | Xiamen Shuangdanma Industrial Development Co., Ltd. ( ), a limited liability company established in the PRC on November 11, 1997 and one of our Controlling Shareholders  |
| 2 3                 | u   |



# DEFINITION

|   |   |
|---|---|
| <p>Yangming Kangyi LP</p> <p>2 3</p>                                  | <p>Fujian Yangming Kangyi Biopharmaceutical Venture Capital LP ( ), a limited partnership established in the PRC on November 17, 2014</p> <p>— u</p>  |
| <p>+EBN products</p> <p>2 + 3</p> <p>w + — &lt;1%~ u</p> <p>w + u</p> | <p>include certain food and skincare products that contain EBN or EBN extracts as an enhancement for elevated nutrition or other benefits. +EBN food products are products that use EBN (with an EBN feed rate of less than 1%) and other food ingredients as raw materials, such as EBN porridge. +EBN skincare products are products that contain EBN or EBN extracts, such as EBN facial masks and EBN essence</p> |
| <p>%</p> <p>2 %<sup>3</sup></p>                                       | <p>per cent</p>   |